<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Topiramate: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Topiramate: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Topiramate: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10006" href="/d/html/10006.html" rel="external">see "Topiramate: Drug information"</a> and <a class="drug drug_patient" data-topicid="11108" href="/d/html/11108.html" rel="external">see "Topiramate: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F229206"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Eprontia;</li>
<li>Qudexy XR;</li>
<li>Topamax;</li>
<li>Topamax Sprinkle;</li>
<li>Trokendi XR</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868442"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACH-Topiramate;</li>
<li>AG-Topiramate;</li>
<li>APO-Topiramate;</li>
<li>Auro-Topiramate;</li>
<li>DOM-Topiramate;</li>
<li>GLN-Topiramate;</li>
<li>JAMP-Topiramate;</li>
<li>Mar-Topiramate [DSC];</li>
<li>MINT-Topiramate;</li>
<li>MYLAN-Topiramate;</li>
<li>PMS-Topiramate;</li>
<li>PRO-Topiramate;</li>
<li>RAN-Topiramate [DSC];</li>
<li>SANDOZ Topiramate [DSC];</li>
<li>TEVA-Topiramate;</li>
<li>Topamax;</li>
<li>Topamax Sprinkle</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1055790"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiseizure Agent, Miscellaneous</span></li></ul></div>
<div class="block don drugH1Div" id="F53462608"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Do not abruptly discontinue therapy; taper dosage gradually to prevent rebound effects.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> Concentrations of oral solution/suspension may vary (commercially available oral solution [25 mg/mL] versus extemporaneously compounded); should be prescribed as mg of topiramate; use caution.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8b623a42-7087-4bbd-8454-7006cc41b187">Neonatal seizures, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neonatal seizures, refractory:</b> Limited data available; optimal dose not established; efficacy results variable:</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm neonate: Oral: Immediate release: Initial: 0.5 to 1 mg/kg/day titrated up daily or every other day by 0.5 to 1 mg/kg/day until seizure control was achieved; effective doses ranged from 3.5 to 8 mg/kg/day; dosing based on a case series of 3 preterm neonates (GA: 28 to 33 weeks; birthweight: 1,105 to 1,595 g) with refractory seizures; all patients remained seizure free ~1 year after discharge with topiramate monotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23007795']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23007795'])">Ref</a></span>). Another case series of 10 preterm neonates used a higher dose of 10 mg/kg/day on day 1 followed by 2 to 5 mg/kg/day, efficacy results not reported; however, 40% of the patients developed necrotizing enterocolitis within 7 days of initiating topiramate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29903834']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29903834'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Term neonate: Oral: Immediate release: 10 mg/kg/day was used in 5 neonates and 3 mg/kg/day was used in 1 neonate who were refractory to phenobarbital. In 4 of the 5 patients who received the higher dose, an absence or reduction in seizure frequency was observed; the neonate who received low dose (3 mg/kg) had no apparent change in seizures; no adverse effects noted required discontinuation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21555055']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21555055'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="12a70f8d-4acf-4dfa-9eae-bcd362753ff2">Neuroprotectant following anoxic injury</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuroprotectant following anoxic injury (with therapeutic hypothermia):</b> Limited data available; optimal dose not established; efficacy results variable:</p>
<p style="text-indent:-2em;margin-left:4em;">Term neonate: Oral: Immediate release: 5 mg/kg/dose on day 1 followed by 3 mg/kg/dose once daily for 2 to 5 days; dosing based on a randomized trial and a prospective case control safety trial. In the randomized, placebo, controlled trial, topiramate at a dose of 5 mg/kg/dose on day 1 followed by 3 mg/kg/dose once daily for 5 days was administered to 49 neonates with hypoxic ischemic encephalopathy and compared to placebo. Topiramate achieved therapeutic concentrations (5 to 20 mg/L) within 24 hours in 36.9% of patients and within 48 hours in 75.5% of the patients. Compared to placebo, patients on topiramate experienced fewer seizures; however, this did not reach statistical significance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31091527']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31091527'])">Ref</a></span>). The safety study used 5 mg/kg/dose on day 1 followed by 3 mg/kg/dose once daily on day 2 and 3 in 11 neonates; no adverse effects were noted (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20553846']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20553846'])">Ref</a></span>). In an earlier pharmacokinetic pilot study of 13 neonates, the same investigators used 5 mg/kg/dose once daily for 3 days; results showed targeted serum concentrations (5 to 20 ng/mL) were achieved in 11 of 13 patients with some accumulation in patients treated with deep hypothermia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19744111']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19744111'])">Ref</a></span>). A dose of 10 mg/kg/dose once daily for 3 days beginning at the time of therapeutic hypothermia (TH) was studied in a randomized trial which compared topiramate with TH (n=21) and TH alone (n=23) in neonates (GA: ≥36 weeks; birthweight: ≥1,800 g) with moderate to severe hypoxic-ischemic encephalopathy; no statistically significant difference in the combined outcome of mortality and severe neurodevelopmental disability at 18 months was found; however, a trend of lower incidence of epilepsy at 18 to 24 months follow-up (14.3% topiramate with TH versus 30.4% TH alone) was noted (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28274169']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28274169'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F229228"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Do not abruptly discontinue therapy; taper dosage gradually to prevent rebound effects.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> Concentration of oral solution/suspension may vary (commercially available oral solution [25 mg/mL] versus extemporaneously compounded); should be prescribed as mg of topiramate; use caution.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="123085ed-3a7b-430b-8aca-b95ee4fe9a79">Infantile spasms; monotherapy or adjunctive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Infantile spasms; monotherapy or adjunctive:</b> Limited data available, efficacy results variable. Not first-line therapy, but may be considered in refractory cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22689735','lexi-content-ref-26835388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22689735','lexi-content-ref-26835388'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children &lt;4 years: Oral: Immediate release: Initial dose: 0.5 to 1 mg/kg/day in divided doses twice daily; may titrate based on clinical response and tolerance in 0.5 to 1 mg/kg/day increments at 5- to 7-day intervals; reported range: 2 to 40 mg/kg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17621500','lexi-content-ref-18382180']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17621500','lexi-content-ref-18382180'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Dosing based on an open-label trial of 544 patients diagnosed with infantile spasms (349 infants; 243 patients on monotherapy); initial topiramate dose was 0.5 to 1 mg/kg/day; doses were titrated as appropriate; reported final dose range: 3.57 to 20 mg/kg/day. After 20 weeks of therapy, 460 patients (84.5%) had a &gt;50% reduction in seizures and seizure freedom was attained in 122 (50.2%) as monotherapy and in 117 (38.9%) as add-on therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18382180']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18382180'])">Ref</a></span>). A higher median initial dose of 1.6 mg/kg/day was reported in another trial of 100 patients (median age: 11.9 months; range: 3.6 to 45.1 months; 36 patients on monotherapy); patients were titrated to an effective final dose; reported final dose range: 2 to 40 mg/kg/day; results showed reduction in infantile spasms from a median of 40 episodes/week to a median of 15 episodes/week and 47 patients had a &gt;50% reduction in all seizures. No difference in efficacy was observed for final dose stratifications of low dose (n=31; 2 to 8 mg/kg/day), medium dose (n=39; 9 to 17 mg/kg/day), or high dose (n=24; 18 to 40 mg/kg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17621500']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17621500'])">Ref</a></span>). However, other trials have reported a poor response to topiramate; in a single-center trial evaluating 31 infants and young children, 9.7% (3/31) achieved remission with topiramate (responder maximum dose range: 25 to 28 mg/kg/day), and all experienced subsequent electroclinical relapse (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26068002']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26068002'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="683d5204-2f9a-4f90-86f2-dc2acc899423">Migraine, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine, prevention: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Pediatric migraine efficacy trials have been observed to have a high placebo response; a meta-analysis has shown that 30% to 61% of subjects receiving placebo report decreased number of migraine attacks or decrease in headache days. Specific to topiramate therapy, trials have shown a reduction in number of headache days and migraine attacks compared to placebo; there is insufficient evidence in pediatric subjects receiving topiramate to demonstrate a 50% reduction in headache frequency, headache day, and migraine disability compared to placebo (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31413170']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31413170'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 6 to &lt;12 years; weight: ≥20 kg: Limited data available: Oral: Immediate release: Initial: 15 mg once daily for 1 week; then increase to 15 mg twice daily for 1 week; then increase to 25 mg twice daily for 7 days; continue to gradually titrate to effect up to target dose of 2 to 3 mg/kg/day divided twice daily; maximum daily dose: 200 mg/<b>day</b> has been reported; however, in older pediatric patients, a targeted daily dose of 100 mg/day is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31413170','lexi-content-ref-16324162']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31413170','lexi-content-ref-16324162'])">Ref</a></span>). Dosing based on a double-randomized, placebo-controlled trial of 90 pediatric patients &lt;12 years (treatment arm: n=59; mean age: 11.3 years as part of a larger trial with a total of 108 pediatric patients receiving topiramate compared to 49 receiving placebo) which showed a mean reduction in migraine days/month with topiramate and significantly more topiramate patients experienced ≥75% reduction in mean monthly migraine days compared to placebo (32% vs 14%) for overall study population; mean maintenance dose: 2 mg/kg/day; treatment duration of maintenance dose: 12 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16324162']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16324162'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate release: Oral: Initial: 25 mg/day once daily at night for 1 week; increase at weekly intervals in 25 mg/day increments as tolerated and indicated to recommended dose of 50 mg twice daily; in a double-blind, placebo-controlled, dose-finding trial of 103 pediatric patients ≥12 years (mean age: 14.2 years), the daily dose of 100 mg/day was shown to significantly decrease frequency of migraine attacks compared to a lower dose of 50 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19255022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19255022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Extended release: Qudexy XR, Trokendi: Oral: Initial: 25 mg/day once daily at night for 1 week; increase at weekly intervals in 25 mg/day increments as tolerated and indicated to recommended dose of 100 mg/day; during titration, some patients may require longer intervals prior to dose escalation.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="90904f46-d8fc-4c30-95fd-95fc7c225148">Seizure disorder, adjunctive therapy for partial onset seizures, primary generalized tonic-clonic seizures, or Lennox Gastaut syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seizure disorder, adjunctive therapy for partial onset seizures, primary generalized tonic-clonic seizures, or Lennox Gastaut syndrome</b>
<b>:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents 2 to 16 years:</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate release: Children and Adolescents 2 to 16 years: Oral: Initial: 1 to 3 mg/kg/day (maximum dose: 25 mg/dose) administered nightly for 1 week; increase at 1- to 2-week intervals in increments of 1 to 3 mg/kg/day in 2 divided doses; titrate dose to response; usual maintenance: 5 to 9 mg/kg/day in 2 divided doses; maximum daily dose: 400 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">Extended release:</p>
<p style="text-indent:-2em;margin-left:8em;">Qudexy XR: Children and Adolescents 2 to 16 years: Oral: Initial: 25 mg once daily (approximately 1 to 3 mg/kg/day) administered nightly for 1 week; increase at 1- to 2-week intervals in increments of 1 to 3 mg/kg/day rounded to the nearest appropriate capsule size administered once daily; titrate dose to response; usual maintenance range: 5 to 9 mg/kg/dose once daily; maximum daily dose: 400 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">Trokendi XR: Children and Adolescents 6 to 16 years, able to swallow capsule whole: Oral: Initial: 25 mg once daily (approximately 1 to 3 mg/kg/day) administered nightly for 1 week; increase at 1- to 2-week intervals in increments of 1 to 3 mg/kg/day rounded to the nearest appropriate capsule size administered once daily; titrate dose to response; usual maintenance: 5 to 9 mg/kg/dose once daily; maximum daily dose: 400 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥17 years:</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate release: Oral: Initial: 25 to 50 mg/day administered daily for 1 week; increase at weekly intervals by 25 to 50 mg/day; administer in 2 divided doses; titrate dose to response. Usual maintenance dose dependent on seizure type; for partial onset seizures or Lennox-Gastaut syndrome: 100 to 200 mg twice daily; usual maintenance dose for primary generalized tonic-clonic seizures 200 mg twice daily; maximum daily dose: 400 mg/<b>day</b>; <b>Note:</b> Doses above 400 mg/day have not been shown to increase efficacy in dose-response studies in adults with partial onset seizures.</p>
<p style="text-indent:-2em;margin-left:6em;">Extended release: Qudexy XR, Trokendi XR: Oral: Initial: 25 to 50 mg once daily for 1 week; increase at weekly intervals by 25 to 50 mg/day once daily; titrate dose to response; longer intervals between dosage adjustment may be used; usual maintenance dose for partial onset seizures or Lennox Gastaut syndrome: 200 to 400 mg once daily; usual maintenance dose for primary generalized tonic-clonic seizures: 400 mg once daily; maximum daily dose: 400 mg/<b>day</b>; higher doses have not been studied.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7e1b49bc-09db-4343-8b19-a9e55313bf87">Seizure disorder, monotherapy for partial onset seizures or primary generalized tonic-clonic seizures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seizure disorder, monotherapy for partial onset seizures or primary generalized tonic-clonic seizures</b>
<b>:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release:</p>
<p style="text-indent:-2em;margin-left:6em;">Children 2 to &lt;10 years: Oral: Initial: 25 mg once daily (in evening); may increase if tolerated to 25 mg twice daily in week 2; thereafter, may increase by 25 to 50 mg/day at weekly intervals over 5 to 7 weeks up to the lower end of the target daily maintenance dosing range (ie, to the minimum recommended maintenance dose); if additional seizure control is needed and therapy is tolerated, may further increase by 25 to 50 mg/day at weekly intervals up to the upper end of the target daily maintenance dosing range (ie, to the maximum recommended maintenance dose):</p>
<p style="text-indent:-2em;margin-left:8em;">Target daily fixed maintenance dosing range:</p>
<p style="text-indent:-2em;margin-left:10em;">≤11 kg: 150 to 250 mg/<b>day</b> in 2 divided doses.</p>
<p style="text-indent:-2em;margin-left:10em;">12 to 22 kg: 200 to 300 mg/<b>day</b> in 2 divided doses.</p>
<p style="text-indent:-2em;margin-left:10em;">23 to 31 kg: 200 to 350 mg/<b>day</b> in 2 divided doses.</p>
<p style="text-indent:-2em;margin-left:10em;">32 to 38 kg: 250 to 350 mg/<b>day</b> in 2 divided doses.</p>
<p style="text-indent:-2em;margin-left:10em;">&gt;38 kg: 250 to 400 mg/<b>day</b> in 2 divided doses.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥10 years and Adolescents: Oral: Initial: 25 mg twice daily; increase at weekly intervals by 50 mg/day increments up to a dose of 100 mg twice daily (week 4 dose); thereafter, may further increase at weekly intervals by 100 mg/day increments up to the recommended maximum dose of 200 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release:</p>
<p style="text-indent:-2em;margin-left:6em;">Qudexy XR:</p>
<p style="text-indent:-2em;margin-left:8em;">Children 2 to 9 years: Oral: Initial: 25 mg once daily (in evening); may increase if tolerated to 50 mg once daily in week 2; thereafter, may increase by 25 to 50 mg/day at weekly intervals over 5 to 7 weeks up to the lower end of the target daily maintenance dosing range (ie, to the minimum recommended maintenance dose); if additional seizure control is needed and therapy is tolerated, may further increase by 25 to 50 mg/day at weekly intervals up to the upper end of the target daily maintenance dosing range (ie, to the maximum recommended maintenance dose); see the following table.</p>
<table border="1" frame="border" rules="all">
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center" colspan="3">
<p style="text-indent:0em;">Monotherapy Targeted Total Daily Fixed Maintenance Doses for Patients 2 to 9 Years</p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>Patient Weight</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Total MINimum Daily Dose (mg/day)</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Total MAXimum Daily Dose (mg/day)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">≤11 kg</p></td>
<td align="center">
<p style="text-indent:0em;">150</p></td>
<td align="center">
<p style="text-indent:0em;">250</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">12 to 22 kg</p></td>
<td align="center">
<p style="text-indent:0em;">200</p></td>
<td align="center">
<p style="text-indent:0em;">300</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">23 to 31 kg</p></td>
<td align="center">
<p style="text-indent:0em;">200</p></td>
<td align="center">
<p style="text-indent:0em;">350</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">32 to 38 kg</p></td>
<td align="center">
<p style="text-indent:0em;">250</p></td>
<td align="center">
<p style="text-indent:0em;">350</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;38 kg</p></td>
<td align="center">
<p style="text-indent:0em;">250</p></td>
<td align="center">
<p style="text-indent:0em;">400</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:8em;">Children ≥10 years and Adolescents: Oral: Initial: 50 mg once daily for 1 week; increase at weekly intervals by 50 mg/day increments up to a dose of 200 mg once daily (week 4 dose); thereafter, may increase at weekly intervals by 100 mg/day increments up to the recommended dose of 400 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Trokendi XR:</p>
<p style="text-indent:-2em;margin-left:8em;">Children 6 to 9 years able to swallow capsule whole: Oral: Initial: 25 mg once daily (in evening); may increase if tolerated to 50 mg once daily in week 2; thereafter, may increase by 25 to 50 mg/day at weekly intervals over 5 to 7 weeks up to the lower end of the target daily maintenance dosing range (ie, to the minimum recommended maintenance dose); if additional seizure control is needed and therapy is tolerated, may further increase by 25 to 50 mg/day at weekly intervals up to the upper end of the target daily maintenance dosing range (ie, to the maximum recommended maintenance dose); see the following table.</p>
<table border="1" frame="border" rules="all">
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center" colspan="3">
<p style="text-indent:0em;">
<b>Monotherapy Targeted Total Daily Fixed Maintenance Doses for Patients 6 to 9 Years of Age</b></p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>Patient Weight</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Total MINimum Daily Dose (mg/day)</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Total MAXimum Daily Dose (mg/day)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">≤11 kg</p></td>
<td align="center">
<p style="text-indent:0em;">150</p></td>
<td align="center">
<p style="text-indent:0em;">250</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">12 to 22 kg</p></td>
<td align="center">
<p style="text-indent:0em;">200</p></td>
<td align="center">
<p style="text-indent:0em;">300</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">23 to 31 kg</p></td>
<td align="center">
<p style="text-indent:0em;">200</p></td>
<td align="center">
<p style="text-indent:0em;">350</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">32 to 38 kg</p></td>
<td align="center">
<p style="text-indent:0em;">250</p></td>
<td align="center">
<p style="text-indent:0em;">350</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;38 kg</p></td>
<td align="center">
<p style="text-indent:0em;">250</p></td>
<td align="center">
<p style="text-indent:0em;">400</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:8em;">Children ≥10 years and Adolescents: Oral: Initial: 50 mg once daily for 1 week; increase at weekly intervals by 50 mg/day increments up to a dose of 200 mg once daily (week 4 dose); thereafter, may increase at weekly intervals by 100 mg/day increments up to the recommended dose of 400 mg once daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of antiseizure therapy:</b> There is currently no standard method for the withdrawal of antiseizure medications in pediatric patients. Successful discontinuation of an antiseizure medication is dependent on several factors including but not limited to: Time of seizure freedom, underlying reason for the seizures, neuroimaging abnormalities, underlying neurodevelopmental status, and medication to be withdrawn (including dose, duration of therapy, and other pharmacokinetic/dynamic considerations) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31990368']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31990368'])">Ref</a></span>). In general, do not abruptly discontinue topiramate therapy; taper dosage gradually to prevent rebound effects. If rapid discontinuation required (eg, adverse effect management), appropriate monitoring necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51192904"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered Kidney Function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents: There are no pediatric-specific dosage adjustments provided in the manufacturer's labeling. Clearance is reduced in patients with CrCl of &lt;70 mL/minute/1.73 m<sup>2</sup> and a dosage adjustment is recommended. Based on adult data, a 50% dosage reduction may be required in patients with a CrCl &lt;70 mL/minute/1.73 m<sup>2</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24725807','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24725807','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis:</b> Children ≥2 years and Adolescents: Removed by hemodialysis, supplemental dose may be required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24725807','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24725807','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51192905"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; however, clearance may be reduced. Carefully adjust dose as plasma concentrations may be increased if normal dosing is used.</p></div>
<div class="block doa drugH1Div" id="F229211"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10006" href="/d/html/10006.html" rel="external">see "Topiramate: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> The dosing recommendations in this monograph are expressed as the total daily dose (ie, per 24 hours) unless stated otherwise. The total daily oral dose is given in 1 to 2 divided doses per day depending on the type of preparation (immediate release is dosed twice daily and extended release is dosed once daily).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d9192803-8b96-41ab-8488-f36d16324eb4">Alcohol use disorder, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Alcohol use disorder, moderate to severe (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Reserve use for patients who do not tolerate or respond to naltrexone or acamprosate, especially if a concomitant seizure disorder is present (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29301420','lexi-content-ref-Holt.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29301420','lexi-content-ref-Holt.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Immediate release: Initial: 25 mg once daily; increase daily dose gradually (eg, in 25 to 50 mg increments weekly) to a maximum of 300 mg/day. Doses &gt;50 mg/day should be administered in 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29301420','lexi-content-ref-12767733','lexi-content-ref-15351769','lexi-content-ref-17925516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29301420','lexi-content-ref-12767733','lexi-content-ref-15351769','lexi-content-ref-17925516'])">Ref</a></span>). Some experts consider alternative therapy if goals are not met within 6 months of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Holt.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Holt.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d98a9598-5db0-4f0c-a3c4-96cdecc00d76">Binge eating disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Binge eating disorder (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 25 mg once daily; increase dose gradually in progressively larger increments of 25 to 100 mg at intervals ≥1 week based on response and tolerability up to 400 mg/day in 1 to 2 divided doses based on chosen formulation (immediate release is dosed twice daily and extended release is dosed once daily) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17258690']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17258690'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8cb4bef1-d180-4d08-bb54-a66edf4aa19a">Cluster headache</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cluster headache (prevention) (alternative agent; adjunctive therapy) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Some experts often use in combination with verapamil (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-May.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-May.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 25 to 50 mg once daily; increase dose gradually in 25 to 50 mg increments at intervals ≥1 week based on response and tolerability, up to a recommended dose of 100 mg/day in 1 to 2 divided doses based on chosen formulation (immediate release is dosed twice daily and extended release is dosed once daily); a further increase up to 200 mg/day may be necessary in some patients for optimal response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16987158','lexi-content-ref-17355498']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16987158','lexi-content-ref-17355498'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b456962a-7b51-4c33-816c-e49a39302cb7">Headache, short-lasting unilateral neuralgiform attacks</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Headache, short-lasting unilateral neuralgiform attacks (prevention) (alternative agent) (off-label use):</b> Based on limited data:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 15 to 25 mg once daily; may increase dose based on response and tolerability in 25 mg increments every 2 weeks up to 100 mg/day in 1 to 2 divided doses based on chosen formulation, and thereafter in 50 mg increments every few weeks up to 400 mg/day in 1 to 2 divided doses based on chosen formulation (immediate release is dosed twice daily and extended release is dosed once daily) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17598764','lexi-content-ref-Matharu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17598764','lexi-content-ref-Matharu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="683d5204-2f9a-4f90-86f2-dc2acc899423">Migraine, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine, prevention:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>An adequate trial for assessment of effect is considered to be at least 2 to 3 months at a therapeutic dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31113373']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31113373'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 25 mg once daily; increase dose in 25 to 50 mg increments at intervals ≥1 week based on response and tolerability, up to 100 mg/day in 1 to 2 divided doses based on chosen formulation (immediate release is dosed twice daily and extended release is dosed once daily). Some patients may require up to 200 mg/day for optimal response; however, adverse effects may increase (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23797676']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23797676'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3bdc9ea7-289f-4752-8056-e3eef3f779c9">Seizures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seizures:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> FDA-approved as monotherapy and adjunctive therapy for focal (partial) onset seizures and primary generalized tonic-clonic seizures, or as adjunctive therapy for Lennox-Gastaut syndrome; may be used off label for other seizure types.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Monotherapy:</i>
<b>Oral:</b> Initial: 50 mg/day; increase dose in 50 mg increments at weekly intervals based on response and tolerability up to 200 mg/day in 1 to 2 divided doses based on chosen formulation; thereafter, may further increase in 100 mg increments at weekly intervals up to 400 mg/day in 1 to 2 divided doses based on chosen formulation (immediate release is dosed twice daily and extended release is dosed once daily).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Adjunctive therapy:</i>
<b>Oral:</b> Initial: 25 to 50 mg/day; increase in 25 to 50 mg increments at weekly intervals based on response and tolerability up to 400 mg/day in 1 to 2 divided doses based on chosen formulation (immediate release is dosed twice daily and extended release is dosed once daily).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f4c334ea-fa8a-4c1e-a320-afcdef036c71">Tremor, essential</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tremor, essential (alternative agent for patients who fail preferred therapies) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 25 mg once or twice daily; increase dose gradually in increments of 25 to 50 mg at intervals ≥1 week based on response and tolerability up to 400 mg/day in 1 to 2 divided doses based on chosen formulation (immediate release is dosed twice daily and extended release is dosed once daily) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22013182','lexi-content-ref-18382182','lexi-content-ref-16436648']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22013182','lexi-content-ref-18382182','lexi-content-ref-16436648'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="de99d55e-4888-427e-b028-9ad02bd5033f">Weight gain, antipsychotic-induced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Weight gain, antipsychotic-induced (alternative agent; adjunct to behavioral and antipsychotic modifications) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 50 mg/day; increase in 25 to 50 mg increments at weekly intervals based on response and tolerability up to a recommended dose of 200 mg/day in 1 to 2 divided doses based on chosen formulation (immediate release is dosed twice daily and extended release is dosed once daily) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Jarskog.1','lexi-content-ref-16062095','lexi-content-ref-23216388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Jarskog.1','lexi-content-ref-16062095','lexi-content-ref-23216388'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosing conversion:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Between IR and ER formulations:</i> Convert using same total daily dose but adjust frequency as indicated for the IR (2 times daily) and ER (once daily) products.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Between ER formulations:</i> Bioequivalence has not been demonstrated between Trokendi XR and Qudexy XR.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Discontinuation of therapy:</b> In patients receiving topiramate long-term, unless safety concerns require a more rapid withdrawal, topiramate should be withdrawn gradually over a few weeks to several months to minimize the potential of seizures or other withdrawal symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Schachter.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Schachter.1'])">Ref</a></span>). In clinical trials, adult doses were decreased by 50 to 100 mg each week over 2 to 8 weeks for seizure treatment, and by 25 to 50 mg each week for migraine prophylaxis.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991605"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24725807','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24725807','lexi-content-ref-manu.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥70 to &lt;130 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;70 mL/minute/1.73 m<sup>2</sup>: Reduce dose to 50% of the indication-specific usual dose and titrate more slowly.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Young patients (&lt;55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> No pharmacokinetic data available; empiric dose increases may be necessary in certain situations (eg, urgent seizure control) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzable (50%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24725807']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24725807'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Reduce dose to 50% of the indication-specific usual dose and titrate more slowly. Since topiramate is significantly cleared by hemodialysis, supplemental doses (eg, 50% of the total daily dose) post hemodialysis are recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25929593','lexi-content-ref-16970741']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25929593','lexi-content-ref-16970741'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Likely to be dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Reduce dose to 50% of the indication-specific usual dose and titrate more slowly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) unless otherwise noted.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Reduce dose to 50% of the indication-specific usual dose and titrate more slowly. Significant removal of topiramate by CRRT is likely, and dose increases may be required based on patient response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19896679','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19896679','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Reduce dose to 50% of the indication-specific usual dose and titrate more slowly. Give supplemental dose after completion of PIRRT (eg, 50% of the total daily dose). May titrate based on patient response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988830"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, topiramate clearance may be reduced in hepatic impairment. Use with caution.</p></div>
<div class="block arsc drugH1Div" id="F55159686"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">CNS effects/cognitive dysfunction</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Topiramate is associated with a range of effects involving the central nervous system (CNS) in all ages. Most common are dose-related sedative effects (eg, <b>dizziness, drowsiness,</b>
<b>fatigue</b>). Additionally, topiramate has been associated with both short-term and long-term <b>cognitive dysfunction</b> in both children and adults, even at low doses (≤100 mg/day), including <b>disturbance in attention</b>, <b>memory impairment</b>, and <b>language problems</b>. Topiramate-associated cognitive dysfunction includes declines in verbal fluency, attention/concentration, processing speed, language skills, perception, working memory, reduced IQ, poor verbal fluency, abnormal thinking, and word-finding deficits (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12614389']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12614389'])">Ref</a></span>). Topiramate is also associated with psychiatric disturbances (eg, <b>aggressive behavior</b>, <b>mood disorder</b>, <b>anxiety,</b>
<b>depression, exacerbation of depression</b>), particularly in patients with previous history of depression or cognitive adverse reactions. Topiramate is also associated with <b>paresthesia</b>. The numbness and tingling of topiramate paresthesia are generally self-limiting, resolving over 2 to 3 months of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23861645','lexi-content-ref-26809953']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23861645','lexi-content-ref-26809953'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related (sedative effects; other effects may involve multiple mechanisms). Multiple effects on receptors within the CNS including sodium channel blockade, L-type calcium channel blockade (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10768302']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10768302'])">Ref</a></span>), potentiation of gamma-amino butyric acid (GABA) transmission, inhibition of glutamate neuroexcitatory pathways through AMPA and kainate receptors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10768299','lexi-content-ref-9264038']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10768299','lexi-content-ref-9264038'])">Ref</a></span>). Topiramate is also a weak inhibitor of type II and type IV carbonic anhydrase (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15197104']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15197104'])">Ref</a></span>). It has been speculated that rapid titration may increase the relative GABA effects leading to more prominent psychiatric symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12752464','lexi-content-ref-19178563']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12752464','lexi-content-ref-19178563'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied. Drowsiness and fatigue may occur early in therapy. Psychiatric effects may be delayed, with an onset up to 6 weeks after initiation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10452922','lexi-content-ref-25083242','lexi-content-ref-24434533']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10452922','lexi-content-ref-25083242','lexi-content-ref-24434533'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Sedative effects:</p>
<p style="text-indent:-2em;margin-left:8em;">• Dose-related</p>
<p style="text-indent:-2em;margin-left:6em;">Cognitive impairment:</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher initial dose and/or rapid titration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23861645','lexi-content-ref-25083242']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23861645','lexi-content-ref-25083242'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25083242']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25083242'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• High working memory capacity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30124584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30124584'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Pediatric patients (6 to 11 years of age)</p>
<p style="text-indent:-2em;margin-left:8em;">• Serum drug concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25083242']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25083242'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Psychiatric disturbances:</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher initial dose and/or rapid titration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23861645','lexi-content-ref-25083242']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23861645','lexi-content-ref-25083242'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of febrile seizures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12752464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12752464'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Personal or family history of psychiatric disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12752464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12752464'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Previous psychotic history (for psychosis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31252268']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31252268'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Paresthesia:</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26809953']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26809953'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26809953']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26809953'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Patients receiving topiramate for migraine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26809953']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26809953'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Metabolic acidosis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Topiramate is associated with <b>hyperchloremic</b>
<b>metabolic acidosis</b> (nonanion gap) in adult and pediatric patients; it may be more common and more severe in infants and children &lt;2 years of age. Metabolic acidosis may be asymptomatic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30755834','lexi-content-ref-11442157']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30755834','lexi-content-ref-11442157'])">Ref</a></span>). Chronic acidosis may predispose individuals to <b>nephrolithiasis</b>, <b>nephrocalcinosis</b>, and osteomalacia/osteoporosis in all ages. <b>Decreased bone mineral density</b> (BMD) has been reported in all pediatric age groups, with ages 6 to 9 years most commonly affected. <b>Linear skeletal growth rate below expectation</b> has been observed in pediatric patients; a similar trend has also been observed for body weight.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> May be dose-related; inhibition of carbonic anhydrase with increased renal bicarbonate excretion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30755834']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30755834'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; metabolic acidosis can occur at any time during treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• May be dose-related; however, metabolic acidosis may occur at doses as low as 50 mg/day</p>
<p style="text-indent:-2em;margin-left:6em;">• Conditions that predispose to acidosis (eg, hepatic, kidney, and/or respiratory impairment)</p>
<p style="text-indent:-2em;margin-left:6em;">• Ketogenic diet (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12199733']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12199733'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Diarrhea</p>
<p style="text-indent:-2em;margin-left:6em;">• Status epilepticus</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent treatment with other drugs which may cause acidosis (eg, zonisamide, acetazolamide)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Nephrolithiasis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Topiramate increases the risk of <b>nephrolithiasis</b> between 2 to 4 times that of the untreated population. Kidney stones have been reported in both adults and pediatric patients.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; exhibits weak carbonic anhydrase inhibitory properties and may elevate the pH of the urine while decreasing urinary citrate concentrations, predisposing to calcium phosphate stone formation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16997051']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16997051'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; occurs after long term therapy, usually months to years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21165738']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21165738'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent medications known to cause metabolic acidosis</p>
<p style="text-indent:-2em;margin-left:6em;">• Ketogenic diet (conflicting data) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12366731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12366731'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Males</p>
<p style="text-indent:-2em;margin-left:6em;">• Dehydration</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Ocular effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Topiramate is associated with <b>acute myopia</b>
<b>with secondary </b>
<b>angle-closure glaucoma</b> in children and adults. Also associated with <b>choroidal effusion</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29063980']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29063980'])">Ref</a></span>) and <b>visual field defect</b>, <b>scotoma</b>, and <b>maculopathy</b>, which may occur without elevation of intraocular pressure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23015022','lexi-content-ref-27229356']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23015022','lexi-content-ref-27229356'])">Ref</a></span>). Bilateral hypopyon <b>uveitis </b>and <b>choroidal detachment</b> have also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34315425']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34315425'])">Ref</a></span>). Most visual field defects were reversible with discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Not established; may be related to alterations in ion transfer (sodium and carbon dioxide), idiosyncratic swelling of the ciliary body, and displacement of lens and ciliary body, leading to acute angle closure and elevation of intraocular pressure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20443647']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20443647'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; typically within 1 month of initiation but has occurred as early as 9 days after initiation (2 days after dose increase) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30591244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30591244'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Oligohidrosis/hyperthermia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Topiramate is associated with decreased sweat production (<b>hypohidrosis</b>) and symptoms of heat intolerance including facial flushing, lethargy, itching sensation, and irritability with <b>hyperthermia</b> in all ages. Some episodes may be severe, requiring hospitalization and/or resulting in long-term sequelae (ataxia and tremor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15795554']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15795554'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; inhibition of carbonic anhydrase leading to a reduction in sweat production without peripheral nervous system involvement (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12760427','lexi-content-ref-19050411']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12760427','lexi-content-ref-19050411'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; from within 2 weeks to 2 months after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12760427','lexi-content-ref-17138020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12760427','lexi-content-ref-17138020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Exercise and higher environmental temperature (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12760427']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12760427'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12760427']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12760427'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of other drugs which may inhibit carbonic anhydrase or drugs with anticholinergic activity</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Suicidal ideation/tendencies</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antiseizure drugs (AEDs) have been associated with <b>suicidal ideation</b> and <b>suicidal tendencies</b>. However, the FDA meta-analysis has been criticized due to several limitations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19496806','lexi-content-ref-22994856']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19496806','lexi-content-ref-22994856'])">Ref</a></span>). The risk of suicide is increased in epilepsy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19453718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19453718'])">Ref</a></span>), but the occurrence of suicidal ideation/tendencies in epilepsy is multifactorial. While some AEDs (but not all) have been associated with treatment-emergent psychiatric effects such as anxiety and depression, other factors such as postictal suicidal behavior and pertinent patient history must also be evaluated to provide an accurate assessment of risk for any individual drug (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22994856']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22994856'])">Ref</a></span>). In one case report, the onset of topiramate-associated suicidal ideation corresponded to an increase in topiramate dose followed by the appearance of depressive symptoms. The patient was described as euthymic with the resolution of this symptom within a week of discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12655915']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12655915'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Not established; associated with depression and anxiety, which may potentially be related to suicidal ideation and tendencies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12655915','lexi-content-ref-21479999']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12655915','lexi-content-ref-21479999'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; peak incidence of suicidality across AEDs (not specific to individual agents) has been noted to occur between 1 and 12 weeks of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28190254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28190254'])">Ref</a></span>). A review of clinical trials noted that risk extended from 1 week to 24 weeks of therapy, corresponding to the duration of most trials.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>• </i>May correspond to dose increases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12655915']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12655915'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>• </i>History of depression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20818889']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20818889'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>• </i>Use in conditions other than epilepsy, depression, or bipolar disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20818889']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20818889'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>• </i>Higher initial dose and/or rapid titration may increase risk for psychiatric disturbances (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12752464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12752464'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>• </i>Family and personal psychiatric history (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12752464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12752464'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>• </i>Family history of epilepsy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12752464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12752464'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>• </i>History of febrile seizures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12752464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12752464'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Weight loss/anorexia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Weight loss</b> was originally observed as an adverse reaction in several trials for various indications with topiramate. More recently, topiramate has been explored therapeutically to promote weight loss (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21684121']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21684121'])">Ref</a></span>). Weight loss may be significant in all ages. In a typical series of adult patients with epilepsy, a loss of 3 kg was reported in the first 3 months of therapy, which increased to 5.9 kg after 1 year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12690085']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12690085'])">Ref</a></span>). The exacerbation and development of <b>eating disorder</b>, including <b>anorexia</b> and bulimia, has been reported in adolescents receiving topiramate for migraines or chronic headaches and an adult receiving topiramate for epilepsy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25847809','lexi-content-ref-12450969']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25847809','lexi-content-ref-12450969'])">Ref</a></span>). Of interest, topiramate has been used to successfully decrease binge eating frequency in binge eating disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27367316']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27367316'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Not established; reduced caloric intake has been observed, while additional proposed mechanisms include hormonal influences on energy production (via leptin, adiponectin, and insulin resistance) and changes in glucose and lipid metabolism via carbonic anhydrase inhibition (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12690085','lexi-content-ref-21684121']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12690085','lexi-content-ref-21684121'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; typically reported during the first 4 to 6 months of therapy and may continue for at least a year, then trend toward baseline levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21684121']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21684121'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Weight loss:</p>
<p style="text-indent:-2em;margin-left:8em;">• Duration of treatment and high baseline body mass index (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21684121']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21684121'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Daily dose and sex (inconsistent associations) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21684121']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21684121'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Development of eating disorders:</p>
<p style="text-indent:-2em;margin-left:8em;">• History of eating disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25847809']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25847809'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Dieting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25847809']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25847809'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Cognitive symptoms of eating disorders (eg, body image distortion, fear of gaining weight, drive for thinness) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25847809']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25847809'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Patients with migraine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25847809']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25847809'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F229172"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions are reported for monotherapy in adult and pediatric patients unless otherwise specified. A wide range of dosages were studied. Incidence of adverse reactions was frequently lower in the pediatric population studied, unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum bicarbonate (children and adolescents: 67%; &lt;17 mEq/L and ≥5 mEq/L decrease from pretreatment: 11%; average decrease of 4 mEq/L at dose of 400 mg/day in adults and 6 mg/kg/day in children)<span class="lexi-table-link-container"> (<a aria-label="Decreased Serum Bicarbonate table link" class="lexi-table-link" data-table-id="lexi-content-decreased-serum-bicarbonate" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-decreased-serum-bicarbonate')">table 1</a>)</span><span class="table-link" style="display:none;">Decreased Serum Bicarbonate</span>, hyperammonemia (adolescents: 14% to 26%)<span class="lexi-table-link-container"> (<a aria-label="Hyperammonemia table link" class="lexi-table-link" data-table-id="lexi-content-hyperammonemia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hyperammonemia')">table 2</a>)</span><span class="table-link" style="display:none;">Hyperammonemia</span>, weight loss (4% to 17%)<span class="lexi-table-link-container"> (<a aria-label="Weight Loss table link" class="lexi-table-link" data-table-id="lexi-content-weight-loss" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-weight-loss')">table 3</a>)</span><span class="table-link" style="display:none;">Weight Loss</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Decreased Serum Bicarbonate" frame="border" id="lexi-content-decreased-serum-bicarbonate" rules="all">
<caption style="text-align:center;">
<b>Topiramate: Adverse Reaction: Decreased Serum Bicarbonate</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Topiramate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">67%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">~6 mg/kg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjunctive treatment of Lennox-Gastaut syndrome or refractory partial-onset seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≤2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">~6 mg/kg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjunctive treatment of Lennox-Gastaut syndrome or refractory partial-onset seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">&lt;17 mEq/L and &gt;5 mEq/L decrease from pretreatment</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hyperammonemia" frame="border" id="lexi-content-hyperammonemia" rules="all">
<caption style="text-align:center;">
<b>Topiramate: Adverse Reaction: Hyperammonemia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Topiramate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">26%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">100 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Migraine</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Migraine</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Weight Loss" frame="border" id="lexi-content-weight-loss" rules="all">
<caption style="text-align:center;">
<b>Topiramate: Adverse Reaction: Weight Loss</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Topiramate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Topiramate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Epilepsy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">77</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Epilepsy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">74</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">46</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">45</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">100 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">48</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">45</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Epilepsy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">159</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Epilepsy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">160</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">100 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">386</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">445</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">235</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">445</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (adolescents and adults: 6% to 15%), anorexia (adolescents and adults: 4% to 15%)<span class="lexi-table-link-container"> (<a aria-label="Anorexia table link" class="lexi-table-link" data-table-id="lexi-content-anorexia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-anorexia')">table 4</a>)</span><span class="table-link" style="display:none;">Anorexia</span>, diarrhea (2% to 11%), dysgeusia (adolescents and adults: 3% to 15%), nausea (adolescents and adults: 8% to 13%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Anorexia" frame="border" id="lexi-content-anorexia" rules="all">
<caption style="text-align:center;">
<b>Topiramate: Adverse Reaction: Anorexia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Topiramate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Topiramate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">100 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">48</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">45</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">46</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">45</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Epilepsy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">159</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Epilepsy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">160</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">100 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">386</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">445</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">235</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">445</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (dose-related) (adolescents and adults: 6% to 14%)<span class="lexi-table-link-container"> (<a aria-label="Dizziness table link" class="lexi-table-link" data-table-id="lexi-content-dizziness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dizziness')">table 5</a>)</span><span class="table-link" style="display:none;">Dizziness</span>, drowsiness (dose-related) (adolescents and adults: 2% to 15%)<span class="lexi-table-link-container"> (<a aria-label="Drowsiness table link" class="lexi-table-link" data-table-id="lexi-content-drowsiness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-drowsiness')">table 6</a>)</span><span class="table-link" style="display:none;">Drowsiness</span>, fatigue (dose-related) (7% to 15%)<span class="lexi-table-link-container"> (<a aria-label="Fatigue table link" class="lexi-table-link" data-table-id="lexi-content-fatigue" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-fatigue')">table 7</a>)</span><span class="table-link" style="display:none;">Fatigue</span>, memory impairment (1% to 11%)<span class="lexi-table-link-container"> (<a aria-label="Memory Impairment table link" class="lexi-table-link" data-table-id="lexi-content-memory-impairment" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-memory-impairment')">table 8</a>)</span><span class="table-link" style="display:none;">Memory Impairment</span>, paresthesia (adolescents and adults: 19% to 51%; children and adolescents: 3% to 12%)<span class="lexi-table-link-container"> (<a aria-label="Paresthesia table link" class="lexi-table-link" data-table-id="lexi-content-paresthesia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-paresthesia')">table 9</a>)</span><span class="table-link" style="display:none;">Paresthesia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dizziness" frame="border" id="lexi-content-dizziness" rules="all">
<caption style="text-align:center;">
<b>Topiramate: Adverse Reaction: Dizziness</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Topiramate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Topiramate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">100 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">48</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">45</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">46</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">45</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Epilepsy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">159</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Epilepsy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">160</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">100 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">386</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">445</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">235</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">445</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Drowsiness" frame="border" id="lexi-content-drowsiness" rules="all">
<caption style="text-align:center;">
<b>Topiramate: Adverse Reaction: Drowsiness</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Topiramate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Topiramate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Epilepsy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">160</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Epilepsy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">159</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">235</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">445</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">100 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">386</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">445</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">46</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">45</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">100 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">48</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">45</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Fatigue" frame="border" id="lexi-content-fatigue" rules="all">
<caption style="text-align:center;">
<b>Topiramate: Adverse Reaction: Fatigue</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Topiramate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Topiramate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">100 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">48</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">45</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">46</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">45</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">100 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">386</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">445</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">235</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">445</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Memory Impairment" frame="border" id="lexi-content-memory-impairment" rules="all">
<caption style="text-align:center;">
<b>Topiramate: Adverse Reaction: Memory Impairment</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Topiramate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Topiramate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Epilepsy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">77</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Epilepsy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">74</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Epilepsy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">159</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Epilepsy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">160</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">235</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">445</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">100 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">386</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">445</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Paresthesia" frame="border" id="lexi-content-paresthesia" rules="all">
<caption style="text-align:center;">
<b>Topiramate: Adverse Reaction: Paresthesia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Topiramate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Topiramate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Epilepsy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">77</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Epilepsy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">74</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">46</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">45</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">100 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">48</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">45</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">40%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Epilepsy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">159</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">21%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Epilepsy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">160</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">51%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">100 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">386</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">445</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">35%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">235</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">445</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Decreased bone mineral density (children and adolescents: 21% [n=63])</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Upper respiratory tract infection (13% to 26%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (1% to 12%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing (children and adolescents: 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris (adolescents and adults: 2% to 3%), alopecia (1% to 4%), pruritus (adolescents and adults: 1% to 4%), skin rash (1% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido (adolescents and adults: 3%), intermenstrual bleeding (children and adolescents: 3%), menstrual disease (adolescents and adults: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (adolescents and adults: 1% to 4%), dyspepsia (adolescents and adults: 4% to 5%), gastritis (adolescents and adults: 3%), gastroenteritis (adolescents and adults: 3%), xerostomia (adolescents and adults: 1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Cystitis (adolescents and adults: 1% to 3%), premature ejaculation (adolescents and adults: 3%), urinary frequency (2% to 3%), urinary incontinence (children and adolescents: 1% to 3%), urinary tract infection (adolescents and adults: 4%), vaginal hemorrhage (adolescents and adults: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (children and adolescents: 1% to 3%), hemorrhage (4% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased gamma-glutamyl transferase (adolescents and adults: 1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (2% to 8%), viral infection (3% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (adolescents and adults: 4% to 6%)<span class="lexi-table-link-container"> (<a aria-label="Anxiety table link" class="lexi-table-link" data-table-id="lexi-content-anxiety" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-anxiety')">table 10</a>)</span><span class="table-link" style="display:none;">Anxiety</span>, asthenia (3% to 6%), ataxia (adolescents and adults: 3% to 4%), behavioral problems (children and adolescents: 3%), cognitive dysfunction (1% to 6%) (literature suggests higher incidence; Lee 2006; Mula 2012), confusion (3%), depression (adolescents and adults: 7% to 9%; children and adolescents: 3%), disturbance in attention, hypertonia (adolescents and adults: 3%), hypoesthesia (adolescents and adults: 4% to 7%), insomnia (adolescents and adults: 6% to 9%), lack of concentration, language problems (adolescents and adults: 6% to 7%)<span class="lexi-table-link-container"> (<a aria-label="Language Problems table link" class="lexi-table-link" data-table-id="lexi-content-language-problems" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-language-problems')">table 11</a>)</span><span class="table-link" style="display:none;">Language Problems</span>, mood disorder (1% to 8%), nervousness (adolescents and adults: 4%), psychomotor impairment (adolescents and adults: 2% to 5%) (literature suggests higher incidence) (Javed 2015)<span class="lexi-table-link-container"> (<a aria-label="Psychomotor Impairment table link" class="lexi-table-link" data-table-id="lexi-content-psychomotor-impairment" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-psychomotor-impairment')">table 12</a>)</span><span class="table-link" style="display:none;">Psychomotor Impairment</span>, vertigo (children and adolescents: 3%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Anxiety" frame="border" id="lexi-content-anxiety" rules="all">
<caption style="text-align:center;">
<b>Topiramate: Adverse Reaction: Anxiety</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Topiramate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Topiramate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Epilepsy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">159</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Epilepsy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">160</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">100 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">386</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">445</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">235</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">445</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Language Problems" frame="border" id="lexi-content-language-problems" rules="all">
<caption style="text-align:center;">
<b>Topiramate: Adverse Reaction: Language Problems</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Topiramate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Topiramate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">235</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">445</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">100 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">386</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">445</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Psychomotor Impairment" frame="border" id="lexi-content-psychomotor-impairment" rules="all">
<caption style="text-align:center;">
<b>Topiramate: Adverse Reaction: Psychomotor Impairment</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Topiramate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Topiramate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Epilepsy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">159</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Epilepsy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">160</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">235</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">445</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">100 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">386</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">445</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (adolescents and adults: 3% to 7%), lower extremity pain (adolescents and adults: 2% to 3%), muscle spasm (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (adolescents and adults: 4%), conjunctivitis (adolescents and adults: 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Nephrolithiasis (adolescents and adults: 3%) (literature suggests higher incidence) (Giannapoulou 2015; Maalouf 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (1% to 5%), cough (adolescents and adults: 2% to 7%), dyspnea (adolescents and adults: 1% to 3%), epistaxis (children and adolescents: 4%), pharyngitis (adolescents and adults: 5% to 6%), rhinitis (2% to 7%), sinusitis (1% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Accidental injury (adolescents and adults: 6% to 9%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Hematologic &amp; oncologic: Major hemorrhage (children)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension, orthostatic hypotension, syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Abnormal serum phosphorus level (decreased), hyperchloremia, increased serum total protein, increased uric acid</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gingival hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased neutrophils, decreased white blood cell count, eosinophilia, thrombocytosis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Linear skeletal growth rate below expectation (reductions in mean annual change from baseline in weight and height compared to control group), myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Scotoma</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Bullous rash, erythema multiforme, hypohidrosis (more common in pediatric patients) (Ben-Zeev 2003), pemphigus (Alkhalifah 2017), Stevens-Johnson syndrome, toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperchloremic metabolic acidosis (nonanion gap) (Sinha 2018; Ture 2016), severe hypokalemia (Muaddi 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Pancreatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Anorgasmia (Chen 2017), urinary retention (Li 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic failure (Tsien 2016), hepatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aggressive behavior (Hansen 2018), eating disorder (Lebow 2015), hallucination (Register 2017), hyperammonemic encephalopathy (usually in combination with valproate) (Tantikittichaikul 2015; Yamamoto 2013), hyperthermia (more common in pediatric patients) (Galicia 2005), mania (Duan 2019), myoclonus (Rissardo 2020), psychosis (Mula 2003), restless leg syndrome (Rissardo 2020), suicidal ideation (Abraham 2003), suicidal tendencies</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Acute myopia with secondary angle-closure glaucoma (Sierra-Rodrigues 2019), choroidal detachment (Tyagi 2021), choroidal effusion (Lau 2018), maculopathy (Gualtieri 2013), uveitis (bilateral hypopyon) (Tyagi 2021), visual field defect (Gualtieri 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Calcium nephrolithiasis (Barnett 2018), renal tubular acidosis (Muaddi 2021)</p></div>
<div class="block coi drugH1Div" id="F229187"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Extended release: Recent alcohol use (ie, within 6 hours prior to and 6 hours after administration) (Trokendi XR only); patients with metabolic acidosis who are taking concomitant metformin (Qudexy XR only).</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">Immediate release: There are no contraindications listed in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to topiramate or any component of the formulation or container; pregnancy and women in childbearing years not using effective contraception (migraine prophylaxis only).</p></div>
<div class="block war drugH1Div" id="F229169"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use caution with hepatic impairment; clearance may be reduced. Dosage adjustment may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use caution with renal impairment; clearance may be reduced. Dosage adjustment may be required.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adults: Use with caution; dosage adjustment may be necessary. Weight loss, cognitive impairment, sedation, and gait/balance disturbances may be more pronounced in the older adult cohort (Sommer 2010).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Withdrawal: Do not discontinue abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal. Doses were also gradually withdrawn in migraine prophylaxis studies (decreased in weekly intervals by 25 to 50 mg/day).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878655"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Necrotizing enterocolitis (NEC) has been reported in neonates; a case series of 10 preterm neonates (GA: 23 to 36 weeks; birthweight: 440 to 2,100 g) who received topiramate at a dose of 10 mg/kg on day 1, followed by 5 mg/kg/dose once daily for treatment of neonatal seizures reported the development of NEC within 1 to 7 days following topiramate administration in 4 of 10 (40%) of preterm neonates; one patient even developed symptoms suggesting a recurrence of NEC following reintroduction of topiramate. No causal relationship can be determined; monitor closely (Courchia 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Pediatric patients &lt;24 months of age may be at increased risk for topiramate-associated hyperammonemia, especially when used concurrently with valproic acid; monitor closely for lethargy, vomiting, or unexplained changes in mental status.</p></div>
<div class="block foc drugH1Div" id="F229180"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule ER 24 Hour Sprinkle, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Qudexy XR: 25 mg, 50 mg, 100 mg, 150 mg, 200 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg, 50 mg, 100 mg, 150 mg, 200 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Extended Release 24 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Trokendi XR: 25 mg [contains fd&amp;c blue #1 (brilliant blue), sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Trokendi XR: 50 mg, 100 mg, 200 mg [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c yellow #6 (sunset yellow), sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg, 50 mg, 100 mg, 200 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Sprinkle, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Topamax Sprinkle: 15 mg, 25 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 15 mg, 25 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Eprontia: 25 mg/mL (120 mL, 240 mL, 473 mL) [contains methylparaben, polyethylene glycol (macrogol), propylparaben]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Topamax: 25 mg, 50 mg, 100 mg, 200 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg, 50 mg, 100 mg, 200 mg</p></div>
<div class="block geq drugH1Div" id="F229165"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F229190"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Sprinkle</b> (Qudexy XR Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $11.72</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $15.27</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $30.26</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $37.22</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $41.39</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Sprinkle</b> (Topiramate ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $9.37 - $9.93</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $12.21 - $12.94</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $24.18 - $25.63</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $29.75 - $31.53</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $33.08 - $35.07</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (Topiramate ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $13.28 - $14.02</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $17.30 - $18.26</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $34.27 - $36.18</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $46.88 - $49.49</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (Trokendi XR Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $14.76</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $19.22</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $38.08</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $52.09</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule, sprinkles</b> (Topamax Sprinkle Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $7.44</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $8.99</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule, sprinkles</b> (Topiramate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $2.42</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $2.92</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Eprontia Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg/mL (per mL): $2.86</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Topamax Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $7.86</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $15.69</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $21.43</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $25.09</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Topiramate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $0.09 - $2.55</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $0.14 - $5.10</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $0.21 - $6.96</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $0.34 - $8.15</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868443"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Sprinkle, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Topamax Sprinkle: 15 mg, 25 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Topamax: 25 mg, 100 mg, 200 mg [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg, 50 mg, 100 mg, 200 mg</p></div>
<div class="block exp drugH1Div" id="F11509771"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;display:inline">
<b>Note</b>
<b>: </b>A topiramate solution (25 mg/mL) for oral administration is commercially available.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>20 mg/mL Oral Suspension (ASHP Standard Concentration)</b> (ASHP 2017)</p>
<p style="text-indent:-2em;margin-left:2em;">A 20 mg/mL oral suspension may be made with topiramate tablets or powder, Ora-Plus and Ora-Sweet. Measure out 2,000 mg of topiramate (equivalent tablets or powder). If using tablets, crush in a mortar and reduce to a fine powder. Add 10 mL of Ora-Plus and mix to a uniform paste; mix while adding an additional 40 mL of Ora-Plus in incremental proportions. Add a small amount of Ora-Sweet and mix. Transfer to a calibrated, amber bottle; rinse mortar with Ora-Sweet and add sufficient quantity to make 100 mL. Label "shake well." Stable for 90 days refrigerated or at room temperature (Allen 2017).</p>
<div class="reference">Allen LV Jr. Contemporary compounding: topiramate 20 mg/mL oral suspension. <i>U.S. Pharmacist. </i>2017;42(5):46-47.</div>
</div>
<div class="block admp drugH1Div" id="F52613946"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May be administered without regard to food.</p>
<p style="text-indent:-2em;margin-left:2em;">Immediate release:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral solution (Eprontia): Measure dose with a calibrated measuring device for accurate dose delivery (avoid household spoons).</p>
<p style="text-indent:-2em;margin-left:4em;">Tablets: Broken tablets have a bitter taste; tablets may be crushed, mixed with water, and administered immediately.</p>
<p style="text-indent:-2em;margin-left:4em;">Sprinkle capsules: Swallow sprinkle capsules whole or open and sprinkle contents on small amount of soft food (eg, 1 teaspoonful of applesauce, oatmeal, ice cream, pudding, custard, or yogurt); swallow sprinkle/food mixture immediately; do not chew; do not store for later use; drink fluids after dose to make sure mixture is completely swallowed.</p>
<p style="text-indent:-2em;margin-left:2em;">Extended release:</p>
<p style="text-indent:-2em;margin-left:4em;">Qudexy XR: May be swallowed whole or may be opened and sprinkled on a small amount (~1 teaspoon) of soft food; swallow immediately and do not chew.</p>
<p style="text-indent:-2em;margin-left:4em;">Trokendi XR: Swallow capsules whole; do not sprinkle capsules on food, chew, or crush. Avoid alcohol use within 6 hours prior to and 6 hours after administration.</p></div>
<div class="block adm drugH1Div" id="F229184"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral: </b>Administer without regard to meals. Administer the IR formulation in divided doses. It is not recommended to crush, break, or chew immediate release tablets due to bitter taste. Swallow ER and sprinkle capsules whole. Sprinkle capsules and Qudexy XR capsules may also be opened to sprinkle the entire contents on a small amount (~1 teaspoon) of soft food; swallow immediately and do not chew. Do not store drug/food mixture for future use. Do not sprinkle Trokendi XR capsules on food, chew, or crush. Avoid alcohol use with Trokendi XR capsules within 6 hours prior to and 6 hours after administration. Use a calibrated measuring device to measure oral solution; do not use a household teaspoon or tablespoon.</p>
<p style="text-indent:-2em;margin-left:2em;">Bariatric surgery: Capsule, extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. IR tablet and sprinkle capsule formulations are available. If safety and efficacy can be effectively monitored, no change in formulation or administration is required after bariatric surgery; however, if swallowing is an issue after surgery, Qudexy XR formulation may be sprinkled on a small amount of soft food.</p></div>
<div class="block hazard drugH1Div" id="F49132845"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 3]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block sts drugH1Div" id="F229201"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Extended release capsules: Store at 15°C to 30°C (59°F to 86°F). Protect from moisture. Protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral solution: Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F). Once open discard any part not used after 90 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Sprinkle capsules: Store at or below 25°C (77°F). Protect from moisture.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablets: Store at 15°C to 30°C (59°F to 86°F). Protect from moisture.</p></div>
<div class="block meg drugH1Div" id="F7874884"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Qudexy XR: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F205122s012lbl.pdf%23page%3D60&amp;token=ra7janPAv1YRrOFAM9BKIIny7Lq3oSe9pweWhhM0HSuGnO%2FY5DO9VoQdURuhgws1sfHKt3vu%2BB2wCZ0X7BUvUQ1YHX0%2Btqvk88mAqhf4lWCcctvzJ9bQ82dXT%2Bychfui&amp;TOPIC_ID=12851" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/205122s012lbl.pdf#page=60</a></p>
<p style="text-indent:-2em;margin-left:4em;">Topamax: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F020505s065%2C020844s056lbl.pdf%23page%3D56&amp;token=PIK5mPFSSKw2ldK%2BrMIQXzIlRncqzu51kkKZgEnHAyThfT1vaSBaIrZe%2BkIny8YNmTUw9%2Fo%2B3cTfWCVZovh0D9bu3p1ERH%2FDqu1wBIad4FerSm4guVwUgSsC5AW%2BHfWq&amp;TOPIC_ID=12851" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020505s065,020844s056lbl.pdf#page=56</a></p>
<p style="text-indent:-2em;margin-left:4em;">Trokendi XR: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F201635s030lbl.pdf%23page%3D52&amp;token=4jIkPtnO24IHbDooJ5%2FZVAC0f7nkVoD1s7PNCBrXRa2frfRHJopEy4kmeIm1ReGCUATG%2FnAfSZLsNnEvJrauuIizw2oegf%2F4ILePLHSUHoNF1SJ5tB4sjrL7JZfyJX7J&amp;TOPIC_ID=12851" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201635s030lbl.pdf#page=52</a></p></div>
<div class="block usep drugH1Div" id="F53569211"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Oral:</p>
<p style="text-indent:-2em;margin-left:2em;">Immediate release: Capsules (sprinkle), tablets (Topamax), oral solution (Eprontia): Initial monotherapy of primary generalized tonic-clonic seizures or partial onset seizures (FDA approved in ages ≥2 years and adults); adjunctive treatment of primary generalized tonic-clonic seizures or partial onset seizures (FDA approved in ages ≥2 years and adults); adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (FDA approved in ages ≥2 years and adults); prophylaxis of migraine headache (FDA approved in ages ≥12 years and adults); has also been used for infantile spasms.</p>
<p style="text-indent:-2em;margin-left:2em;">Extended release: Initial monotherapy of primary generalized tonic-clonic seizures or partial onset seizures (Qudexy XR: FDA approved in ages ≥2 years and adults; Trokendi XR: FDA approved in ages ≥6 years and adults); adjunctive treatment of primary generalized tonic-clonic seizures, partial onset seizures, or treatment of seizures associated with Lennox-Gastaut syndrome (Qudexy XR: FDA approved in ages ≥2 years and adults; Trokendi XR: FDA approved in ages ≥6 years and adults); prophylaxis of migraine headache (Qudexy XR and Trokendi XR: FDA approved in ages ≥12 years and adults).</p></div>
<div class="block mst drugH1Div" id="F229250"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Topamax may be confused with Sporanox, TEGretol, TEGretol-XR, Toprol-XL</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Bioequivalence has not been demonstrated between Trokendi XR and Qudexy XR.</p>
<p style="text-indent:-2em;margin-left:4em;">Qudexy XR capsules may be swallowed whole or opened to sprinkle the entire contents on a small amount (~1 teaspoon) of soft food. Do not open and sprinkle Trokendi XR capsules on food, chew, or crush; doing so may disrupt the triphasic release properties.</p>
<p style="text-indent:-2em;margin-left:4em;">Avoid alcohol use with Trokendi XR within 6 hours prior to and 6 hours after administration; concurrent use may result in dose dumping.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F229235"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F229174"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the CNS depressant effect of Topiramate. Alcohol (Ethyl) may increase the serum concentration of Topiramate. This applies specifically to use with the extended-release topiramate capsules (Trokendi XR).  Also, topiramate concentrations may be subtherapeutic in the later portion of the dosage interval. Management: Concurrent use of alcohol within 6 hours of ingestion of extended-release topiramate (Trokendi XR) is contraindicated.  Any use of alcohol with topiramate should be avoided when possible and should only be undertaken with extreme caution.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha-/Beta-Agonists (Indirect-Acting): Carbonic Anhydrase Inhibitors may increase the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amantadine: Carbonic Anhydrase Inhibitors may increase the serum concentration of Amantadine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amitriptyline: Topiramate may enhance the CNS depressant effect of Amitriptyline. Topiramate may increase serum concentrations of the active metabolite(s) of Amitriptyline. Topiramate may increase the serum concentration of Amitriptyline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: Carbonic Anhydrase Inhibitors may decrease the excretion of Amphetamines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the adverse/toxic effect of Topiramate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: Topiramate may enhance the CNS depressant effect of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Topiramate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of other Carbonic Anhydrase Inhibitors. The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Management: Avoid concurrent use of different carbonic anhydrase inhibitors if possible.  Monitor patients closely for the occurrence of kidney stones and with regards to severity of metabolic acidosis.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Hyponatremia-Associated Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flecainide: Carbonic Anhydrase Inhibitors may decrease the excretion of Flecainide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin: May decrease the serum concentration of Topiramate. Topiramate may increase the serum concentration of Fosphenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hormonal Contraceptives: Topiramate may decrease the serum concentration of Hormonal Contraceptives.  Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing topiramate to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: Antiseizure Agents (Sodium Channel Blockers) may enhance the adverse/toxic effect of Lacosamide. Specifically the risk for bradycardia, ventricular tachyarrhythmias, or a prolonged PR interval may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">LamoTRIgine: Topiramate may enhance the arrhythmogenic effect of LamoTRIgine. LamoTRIgine may enhance the CNS depressant effect of Topiramate.  Management: Consider the risk of serious arrhythmias or death versus any expected benefit of lamotrigine in patients receiving concomitant sodium channel blockers. Additionally, if combined, caution patients that CNS depressant effects may be increased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Topiramate may increase the serum concentration of Lithium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the hypokalemic effect of Topiramate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mefloquine: May diminish the therapeutic effect of Antiseizure Agents. Mefloquine may decrease the serum concentration of Antiseizure Agents. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of seizures. If antiseizure drugs are being used for another indication, monitor antiseizure drug concentrations and treatment response closely with concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Memantine: Carbonic Anhydrase Inhibitors may increase the serum concentration of Memantine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetFORMIN: Topiramate may enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk for lactic acidosis may be increased. MetFORMIN may increase the serum concentration of Topiramate. Topiramate may increase the serum concentration of MetFORMIN. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methenamine: Carbonic Anhydrase Inhibitors may diminish the therapeutic effect of Methenamine.  Management: Consider avoiding the concomitant use of medications that alkalinize the urine, such as carbonic anhydrase inhibitors, and methenamine. Monitor for decreased therapeutic effects of methenamine if used concomitant with a carbonic anhydrase inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Antiseizure Agents may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking antiseizure agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May diminish the therapeutic effect of Antiseizure Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orlistat: May decrease the serum concentration of Antiseizure Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: Topiramate may enhance the CNS depressant effect of Perampanel. Topiramate may decrease the serum concentration of Perampanel. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phenytoin: Topiramate may increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Topiramate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pioglitazone: Topiramate may decrease the serum concentration of Pioglitazone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination. Management: Avoid these combinations when possible.Dichlorphenamide use with high-dose aspirin as contraindicated. If another combination is used, monitor patients closely for adverse effects. Tachypnea, anorexia, lethargy, and coma have been reported.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May enhance the hypokalemic effect of Topiramate. Thiazide and Thiazide-Like Diuretics may increase the serum concentration of Topiramate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ulipristal: Topiramate may decrease the serum concentration of Ulipristal. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: Topiramate may enhance the adverse/toxic effect of Valproate Products. Specifically, the risk of hypothermia and hyperammonemia, with or without encephalopathy, may be increased. Valproate Products may decrease the serum concentration of Topiramate. Topiramate may decrease the serum concentration of Valproate Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F229202"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;margin-left:0em;text-align:justify;display:inline">Ketogenic diet may increase the possibility of acidosis and/or kidney stones. Management: Monitor for symptoms of acidosis or kidney stones.</p></div>
<div class="block rep_considerations drugH1Div" id="F52511803"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Effective contraception should be used in females of reproductive potential who are not planning a pregnancy; consider use of alternative medications in patients who wish to become pregnant.</p></div>
<div class="block pri drugH1Div" id="F229191"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on limited data (n=5), topiramate was found to cross the placenta and could be detected in neonatal serum (Ohman 2002).</p>
<p style="text-indent:0em;margin-top:2em;">Topiramate may cause fetal harm if administered to a pregnant patient. An increased risk of oral clefts (cleft lip and/or palate) and for being small for gestational age (SGA) has been observed following in utero exposure. Data from the North American Antiepileptic Drug (NAAED) Pregnancy Registry reported that the prevalence of oral clefts was 1.1% for infants exposed to topiramate during the first trimester of pregnancy, versus 0.36% for infants exposed to a reference antiseizure drug, and 0.12% for infants with no exposure born to mothers without epilepsy; the relative risk of oral clefts in infants exposed to topiramate was calculated to be 9.6 (95% CI: 4 to 23). Data from the NAAED Pregnancy Registry reported that the prevalence of small for gestational age newborns was 19.7% for newborns exposed to topiramate in utero, versus 7.9% for newborns exposed to a reference antiseizure drug, and 5.4% for newborns with no exposure born to mothers without epilepsy. Although not evaluated during pregnancy, metabolic acidosis may be induced by topiramate. Metabolic acidosis during pregnancy may result in adverse effects and fetal death. Pregnant patients and their newborns should be monitored for metabolic acidosis. In general, maternal polytherapy with antiseizure drugs may increase the risk of congenital malformations; monotherapy with the lowest effective dose is recommended. Newborns of patients taking antiseizure medications may be at an increased risk of a 1 minute Apgar score &lt;7 (Harden 2009).</p>
<p style="text-indent:0em;margin-top:2em;">Maternal serum concentrations may decrease during the second and third trimesters of pregnancy; therefore, therapeutic drug monitoring should be considered during pregnancy and postpartum in patients who require therapy (Ohman 2009; Westin 2009).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to topiramate is ongoing. Patients may enroll themselves into the NAAED Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.</p></div>
<div class="block mopp drugH1Div" id="F53569212"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Frequency, duration, and severity of seizure episodes or migraine headaches; renal function; monitor serum electrolytes including baseline and periodic serum bicarbonate, symptoms of metabolic acidosis, complications of chronic acidosis (eg, nephrolithiasis, rickets, reduced growth rates); monitor body temperature and for decreased sweating, especially in warm or hot weather; changes in weight or appetite due to anorexia; monitor serum ammonia concentration in patients with unexplained lethargy, vomiting, or mental status changes; intraocular pressure, symptoms of secondary angle closure glaucoma; signs and symptoms of suicidality (eg, anxiety, depression, behavior changes); signs of skin rash and severe skin reactions.</p></div>
<div class="block rerp drugH1Div" id="F53568865"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Not applicable; plasma topiramate concentrations have not been shown to correlate with clinical efficacy.</p></div>
<div class="block pha drugH1Div" id="F229168"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Antiseizure activity may be due to a combination of potential mechanisms: Blocks neuronal voltage-dependent sodium channels, enhances GABA(A) activity, antagonizes AMPA/kainate glutamate receptors, and weakly inhibits carbonic anhydrase.</p></div>
<div class="block phk drugH1Div" id="F229186"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Immediate-release preparations are bioequivalent (sprinkle capsule and tablet); extended-release capsules (Trokendi XR) administered once daily is bioequivalent to twice daily administration of immediate-release formulations; however, bioequivalence has not been established between Trokendi XR and Qudexy XR.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Good, rapid; immediate release formulation is unaffected by food. A single Trokendi XR dose with a high-fat meal increased the C<sub>max</sub> by 37% and shortened the T<sub>max</sub> to approximately 8 hours; this effect is significantly reduced following repeat administrations. A single Qudexy XR dose with a high-fat meal delayed the T<sub>max</sub> by 4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d:</sub> 0.6 to 0.8 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 15% to 41% (inversely related to plasma concentrations).</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Not extensively metabolized. Minor amounts metabolized in liver via hydroxylation, hydrolysis, and glucuronidation; there is evidence of renal tubular reabsorption; percentage of dose metabolized in liver and clearance are increased in patients receiving enzyme inducers (eg, carbamazepine, phenytoin).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~80% (immediate release).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release:</p>
<p style="text-indent:-2em;margin-left:6em;">Not receiving concomitant enzyme inducers or valproic acid:</p>
<p style="text-indent:-2em;margin-left:8em;">Neonates (full-term) with hypothermia: ~43 hours (Filippi 2009).</p>
<p style="text-indent:-2em;margin-left:8em;">Infants and Children 9 months to &lt;4 years: 10.4 hours (range: 8.5 to 15.3 hours) (Mikaeloff 2004).</p>
<p style="text-indent:-2em;margin-left:8em;">Children 4 to 7 years: Mean range: 7.7 to 8 hours (Rosenfeld 1999).</p>
<p style="text-indent:-2em;margin-left:8em;">Children 8 to 11 years: Mean range: 11.3 to 11.7 hours (Rosenfeld 1999).</p>
<p style="text-indent:-2em;margin-left:8em;">Children and Adolescents 12 to 17 years: Mean range: 12.3 to 12.8 hours (Rosenfeld 1999).</p>
<p style="text-indent:-2em;margin-left:6em;">Receiving concomitant enzyme inducers (eg, carbamazepine, phenytoin, phenobarbital):</p>
<p style="text-indent:-2em;margin-left:8em;">Neonates (full-term) with hypothermia: 26.5 hours (Filippi 2009).</p>
<p style="text-indent:-2em;margin-left:8em;">Infants and Children 9 months to &lt;4 years: 6.5 hours (range: 3.75 to 10.2 hours) (Mikaeloff 2004).</p>
<p style="text-indent:-2em;margin-left:8em;">Children and Adolescents 4 to 17 years: 7.5 hours (Rosenfeld 1999).</p>
<p style="text-indent:-2em;margin-left:6em;">Receiving valproic acid: Infants and Children 9 months to 4 years: 9.2 hours (range: 7.23 to 12 hours) (Mikaeloff 2004).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: 19 to 23 hours (mean: 21 hours).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults with renal impairment: 59 ± 11 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release: Qudexy XR: ~56 hours; Trokendi XR: ~31 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum:</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release:</p>
<p style="text-indent:-2em;margin-left:6em;">Neonates (full-term) with hypothermia: 3.8 hours (Filippi 2009).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children 9 months to &lt;4 years: 3.7 hours (range: 1.5 to 10.2 hours) (Mikaeloff 2004).</p>
<p style="text-indent:-2em;margin-left:6em;">Children 4 to 17 years: Mean range: 1 to 2.8 hours (Rosenfeld 1999).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: Oral solution: 0.5 hours; Tablets: 2 hours; range: 1.4 to 4.3 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release: Qudexy XR: ~20 hours; Trokendi XR: ~24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~70% as unchanged drug); may undergo renal tubular reabsorption.</p>
<p style="text-indent:-2em;margin-left:2em;">Clearance:</p>
<p style="text-indent:-2em;margin-left:4em;">Not receiving concomitant enzyme inducers or valproic acid:</p>
<p style="text-indent:-2em;margin-left:6em;">Neonates (full-term) with hypothermia: 13.4 mL/kg/hour (Filippi 2009).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children 9 months to &lt;4 years: 46.5 mL/kg/hour (range: 30.5 to 70.9 mL/kg/hour) (Mikaeloff 2004).</p>
<p style="text-indent:-2em;margin-left:6em;">Children 4 to 17 years: 27.6 mL/kg/hour (Rosenfeld 1999).</p>
<p style="text-indent:-2em;margin-left:4em;">Receiving concomitant enzyme inducers:</p>
<p style="text-indent:-2em;margin-left:6em;">Neonates (full-term) with hypothermia: 17.9 mL/kg/hour (Filippi 2009).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children 9 months to &lt;4 years: 85.4 mL/kg/hour (range: 46.2 to 135 mL/kg/hour) (Mikaeloff 2004).</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents 4 to 17 years: 60.6 mL/kg/hour (Rosenfeld 1999).</p>
<p style="text-indent:-2em;margin-left:4em;">Receiving valproic acid: Infants and Children 9 months to &lt;4 years: 49.6 mL/kg/hour (range: 26.6 to 60.2 mL/kg/h) (Mikaeloff 2004).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 20 to 30 mL/minute.</p></div>
<div class="block phksp drugH1Div" id="F51204301"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Clearance is reduced 42% in moderately impaired (creatinine clearance [CrCl] 30 to 69 mL/minute/1.73 m<sup>2</sup>) and 54% in severely impaired (CrCl &lt;30 mL/minute/1.73 m<sup>2</sup>) patients. Significantly hemodialyzed; dialysis clearance is 120 mL/minute (4-6 times higher than in adults with normal renal function).</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Clearance is reduced by a mean of 26% in patients with moderate to severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Half-life elimination is longer. Plasma and renal clearance were reduced 21% and 19%, respectively. Reduced clearance resulted in slightly higher C<sub>max</sub> (23% for immediate release; 30% for Trokendi XR) and AUC (25% for immediate release; 44% for Trokendi XR). Topiramate clearance is decreased only to the extent that renal function is reduced. T<sub>max</sub> for Trokendi XR is shorter (16 hours).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F229193"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Ipramax | Maxipra | Topamax</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Apo topiramato | Epilacam | Epistal | Neutop | Topamac | Topictal | Topiramato Cevallos | Trokendi xr | Zinalow</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Topamax | Topilex | Topiramat +pharma | Topiramat 1A Pharma | Topiramat accord | Topiramat actavis | Topiramat Arcana | Topiramat Bluefish | Topiramat Easypharm | Topiramat G.L. | Topiramat Genericon | Topiramat ratiopharm | Topiramat sandoz | Topiramat Stada</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo topiramate | Epiramax | Noumed topiramate | Tamate | Topamax | Topiramate an | Topiramate Ga | Topiramate Generic Health | Topiramate gh | Topiramate Sandoz</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Etopira | Piramed | Topirva | Topmate</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Topamax | Topiramate EG | Topiramate Teva</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Lusitrax | Talopam | Tobanex | Topamax | Topilex | Topiramate accord | Topirax</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Amato | Arasid | Egide | Opera | Tempora | Topamax | Topiramato | Topit | Toptil | Vidmax</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Topamax | Topiramat actavis | Topiramat Desitin | Topiramat Helvepharm | Topiramat mepha | Topiramat orion | Topiramat pfizer | Topiramat sandoz | Topiramat spirig | Topiramat spirig hc | Topiramat teva</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Amato | Biomood | Piracross | Topamax | Topictal | Topivitae | Toprel</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Topamax | Tuo tai</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Conviram | Piramax | Protomax | Topamac | Topamac sprinkle | Topictal | Topilex | Topiramato | Topiramato sandoz | Topirol | Topivitae</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Apo Topiramat | Erravia | Topamax | Topilept | Topilex | Topiragis | Topiramat accord | Topiramat actavis | Topiramat galex | Topiramat orion | Topiramat Pliva | Topiramat ratiopharm | Topiramat sandoz | Topiramat teva | Topiramat Vipharm | Topiramate neuraxpharm | Topiramate Tecnimede</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Topamac | Topamax | Topamax migraene | Topira Q | Topiragamma | Topiramat | Topiramat 1 A Pharma | Topiramat Aaa | Topiramat Acis | Topiramat actavis | Topiramat AL | Topiramat Aurobindo | Topiramat basics | Topiramat Beta | Topiramat Biomo | Topiramat Bluefish | Topiramat CT | Topiramat Desitin | Topiramat Dura | Topiramat glenmark | Topiramat Heumann | Topiramat Hexal | Topiramat Hormosan | Topiramat Janssen | Topiramat Neuraxpharm | Topiramat puren | Topiramat ratiopharm | Topiramat sandoz | Topiramat siga | Topiramat Stada | Topiramat teva | Topiramat Winthrop | Topiramed</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Topiratore</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Neurotoprel | Rondigal | Topamax | Topictal | Topiramato | Topivitae | Toprel | Torlaton</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Topamac | Topictal | Topidol</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Topamax | Topiramate Orion | Topiramate portfarma</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Conviban | Delpiramate | Nancydal | Sprinkazen | Topamax | Topilept</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Acomicil | Epilmax | Fagodol | Roklisan | Topamax | Topibrain | Topimylan | Topiramato Actavis | Topiramato alter | Topiramato amneal | Topiramato aurobindo | Topiramato bluefish | Topiramato Cinfa | Topiramato Combix | Topiramato Davur | Topiramato Kern pharma | Topiramato Normon | Topiramato Pensa | Topiramato pharma combix | Topiramato pharmacia | Topiramato Pharmagenus | Topiramato Qualigen | Topiramato ranbaxy | Topiramato ratiopharm | Topiramato sandoz | Topiramato Stada | Topiramato Tarbis | Topiramato Tecnigen | Topiramato UR | Topiramato urlabs | Topiramato Winthrop</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Topimax | Topiramat accord | Topiramat Mylan | Topiramat orion | Topiramat pfizer | Topiramat ratiopharm | Topiramat sandoz</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Epitomax | Topiramate Actavis | Topiramate Arrow | Topiramate bgr | Topiramate biogaran | Topiramate bluefish | Topiramate EG | Topiramate Intas | Topiramate Mylan | Topiramate Sandoz | Topiramate Teva | Topiramate Zydus</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Topamax | Topiramate milpharm | Topiramate morningside</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Jadix | Pirantal | Topamac | Topepil | Topiramate/actavis | Topiramate/Generics | Topiramate/mylan | Topiramate/Teva | Topiref</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo topiramate | Pms-topiramate | Topamax</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Epiramat | Tiramat | Topamax</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Epilania | Etopro | Talopam | Topamax | Topepsil | Topilex | Topiramat galex | Topiramat orion | Topiramat pfizer | Topiramat teva</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Migratop | Topamax</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Topamax</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Topamax | Topamax sprinkle | Topitrim</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Altop | Elitop | Epimate | Epitop | Leptomate | Monotop | Natrin | Nextop | Ropimate | Seiztop | Sotop | T mate | Topamac | Topamate | Topamed | Topaz | Topcnx | Topema | Topex | Topicon | Topimat | Topiram | Topirate | Topirest | Topirol | Topitab | Topival | Topper | Topse | Topsulant | Torpiza | Ultramate | Urate</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Topimax</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Sincronil | Topamax | Topiramato | Topiramato Accord | Topiramato aurobindo | Topiramato bluefish | Topiramato Doc | Topiramato EG | Topiramato germed | Topiramato hexal | Topiramato mylan generics | Topiramato sandoz | Topiramato Tecnimede | Topiramato Tev | Topiramato Winthrop</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Convumax | Epigrain | Ipramax | Topamax</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Neutop | Topamax</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Boryung topiramate | Ceti | Daewoongbio topiramate | Epitop | Gabatopa | Hanwha topiramate | Pamet | Pitmate | Pms-topiramate | Pondamis | Qudexy er | Qudexy xr | Tomac | Tomax | Topa m | Topacai | Topad | Topalas | Topam | Topama | Topamate | Topamax | Topamax springkle | Topamax sprinkle | Topamed | Topamet | Topamete | Topamin | Topaone | Toparos | Topas | Topathin | Topaz | Topex | Topi | Topican | Topimae | Topimain | Topimax | Topimay | Topimed | Topin | Topins | Topira | Topiramax | Topiramin | Topirapet | Topirat | Topiren | Topirex | Topirid | Topiron | Topit | Topiver | Topmate | Topram | Topramac | Toram | Toramac | Toramate | Toramin | Toraphen | Tpr | Unitopa</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Topamax</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Apo topiramate | Ipramax | Topamax | Topiramate Arrow | Topirate | Toramat</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Oritop | Topamax | Topimark | Topiramate accord | Topiramate Orion | Topiramate portfarma | Topiramate Teva | Topiramate Torrent</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Topamax</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Topamax | Topiramat orion | Topiramate accord | Topiramate elvim | Topiramate Pfizer | Topiramate portfarma</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Topiramate gt</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Acotopa | Anepigran | Arizic | Expliga xr | Lepisitin | Lepsicral | Luxomab | Nabian k | Optiprax | Rantopa | Sindentrit | Surxtop | Tomerzat | Tomzy | Topamax | Topgran | Topiramato | Topiramato nafar | Topreno | Topumate | Tramixin | Tripleland</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Epimate | Ropimate | Topamax | Torate</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Hiltop | Topamax</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Epitomax | Topamax | Topamax sprinkle | Topiramaat | Topiramaat accord | Topiramaat Aurobindo | Topiramaat Bluefish | Topiramaat cf | Topiramaat glenmark | Topiramaat mylan | Topiramaat pch | Topiramaat ratiopharm | Topiramaat sandoz</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Topamax | Topimax | Topiramat Bluefish | Topiramat ratiopharm</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Arrow-topiramate | Topamax</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Piramat | Rondigal | Topamac | Topaz | Topictal | Topiramato | Topiramax | Topirest | Topirol | Topivitae | Toprel</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Epimate | Epitop | Topamax | Topirol | Topvex | Trokendi xr</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">C Zar | Danmate | Epik | Epilock | Erbro | Hitop | Legent | Migg | Neutop | Nuromate | Opamac | Pimate | Regutran | Seziril | Tics g | Tipra | Tiramat | Tomax | Tomigraine | Topagen | Topamax | Topilep | Topira | Topirama | Topiro | Topister | Topival | Topmark | Topmate | Topmin | Toprate | Toprex | Topte | Tritop | Zopir</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Epilania | Epiramat | Epitoram | Erudan | Oritop | Ramatop | Symtopiram | Topamax | Topigen | Topilek | Topimatil | Topiramat Bluefish | Topiramat pfizer | Topiramate Arrow | Topiran | Toramat</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Qudexy xr | Topamax | Topiragen | Topiramate extended release | Trokendi</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Pirepil | Topamax | Topiramato | Topiramato Accord | Topiramato almus | Topiramato aurobindo | Topiramato bluefish | Topiramato bluepharma | Topiramato ciclum | Topiramato clindonim | Topiramato generis | Topiramato Goldfarma | Topiramato GP | Topiramato Mepha | Topiramato ranbaxy | Topiramato sandoz | Topiramato Vida | Topiramato wynn</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Amato topiramato | Biomood | Rondigal | Tazomax | Topamac | Topictal | Topiramato imedic | Topiramato prosalud | Topirato | Toprel | Toramato</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Ipramax | Topamax | Topamax Sprinkle</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Lusitrax | Topilex | Topiramat teva | Zidoxer</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Epitope | Epymax | Maxitopir | Ropimate | Topalepsin | Topamax | Topiramat | Topiramat alsi | Topiramat canon | Topiramat sandoz | Topiramat tl | Topiramat vial | Topiromax | Topsaver | Toreal | Torepimat</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo topiramate | Pms-topiramate | Topamax</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Topimax | Topiramat | Topiramat 2care4 | Topiramat accord | Topiramat actavis | Topiramat Bluefish | Topiramat Orifarm | Topiramat orion | Topiramat ratiopharm | Topiramat sandoz</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Topamax</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Letop | Topamax | Topiramat galex</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Epilania | Erravia | Talopam | Topamax | Topepsil | Topilex | Topimark | Topiramat orion | Topiramat pfizer | Topiramat sandoz | Topiramate neuraxpharm</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Moramax | Pradox | Topamax</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Epitomax</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">As topiram | Noromat | Topamax | Topimol | Xamate</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Epilramate | Levelin | Topaless | Topamax | Topiramate Sandoz | Topiz | Toramate | Trokendi xr | Zydus topiramate</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Epiramat | Rantopir | Topamax</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Amato | Neutop | Rondigal | Tiantol | Topamac | Topictal | Topilep | Topiramato | Topirax</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Migratop | Topamax | Topictal | Topiramato | Topirol | Topitec | Topitol | Triosc</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">ADCO Topiramate | Epimate | Pamiram | Piramax | Sandoz topiramate | Topalex | Topamax | Topirol | Toplep</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Topilept</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Epimate</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt;Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12655915">
<a name="12655915"></a>Abraham G. Topiramate-induced suicidality. <i>Can J Psychiatry</i>. 2003;48(2):127-128. doi:10.1177/070674370304800214<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/12655915/pubmed" id="12655915" target="_blank">12655915</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31252268">
<a name="31252268"></a>Adachi N, Fenwick P, Akanuma N, et al. Increased frequency of psychosis after second-generation antiepileptic drug administration in adults with focal epilepsy. <i>Epilepsy Behav</i>. 2019;97:138-143. doi:10.1016/j.yebeh.2019.06.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/31252268/pubmed" id="31252268" target="_blank">31252268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21961502">
<a name="21961502"></a>Aigner M, Treasure J, Kaye W, Kasper S; WFSBP Task Force on Eating Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders. <i>World J Biol Psychiatry.</i> 2011;12(6):400-443. doi:10.3109/15622975.2011.602720<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/21961502/pubmed" id="21961502" target="_blank">21961502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27510943">
<a name="27510943"></a>Alkhalifah A, Montaudié H, Lacour JP, Lantéri-Minet M, Passeron T. Exacerbation of Hailey-Hailey disease by topiramate. <i>J Eur Acad Dermatol Venereol</i>. 2017;31(4):e185-e186. doi:10.1111/jdv.13909<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/27510943/pubmed" id="27510943" target="_blank">27510943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20818889">
<a name="20818889"></a>Arana A, Wentworth CE, Ayuso-Mateos JL, Arellano FM. Suicide-related events in patients treated with antiepileptic drugs. <i>N Engl J Med</i>. 2010;363(6):542-551. doi:10.1056/NEJMoa0909801<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/20818889/pubmed" id="20818889" target="_blank">20818889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al.<i> Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children. </i>5th ed. American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASHP.1">
<a name="ASHP.1"></a>ASHP. Standardize 4 Safety Initiative Compounded Oral Liquid Version 1.01. July 2017. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/s4s-ashp-oral-compound-liquids.ashx?la=en&amp;hash=4C2E4F370B665C028981B61F6210335AD5D0D1D6.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31990368">
<a name="31990368"></a>Ayuga Loro F, Gisbert Tijeras E, Brigo F. Rapid versus slow withdrawal of antiepileptic drugs. <i>Cochrane Database Syst Rev</i>. 2020;1(1):CD005003. doi:10.1002/14651858.CD005003.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/31990368/pubmed" id="31990368" target="_blank">31990368</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25929593">
<a name="25929593"></a>Bansal AD, Hill CE, Berns JS. Use of antiepileptic drugs in patients with chronic kidney disease and end stage renal disease. <i>Semin Dial</i>. 2015;28(4):404-412. doi:10.1111/sdi.12385<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/25929593/pubmed" id="25929593" target="_blank">25929593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30124584">
<a name="30124584"></a>Barkley CM, Hu Z, Fieberg AM, et al. Individual differences in working memory capacity predict topiramate-related cognitive deficits. <i>J Clin Psychopharmacol</i>. 2018;38(5):481-488. doi:10.1097/JCP.0000000000000949<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/30124584/pubmed" id="30124584" target="_blank">30124584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29854977">
<a name="29854977"></a>Barnett SM, Jackson AH, Rosen BA, Garb JL, Braden GL. Nephrolithiasis and nephrocalcinosis from topiramate therapy in children with epilepsy. <i>Kidney Int Rep</i>. 2018;3(3):684-690. doi:10.1016/j.ekir.2018.02.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/29854977/pubmed" id="29854977" target="_blank">29854977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19453718">
<a name="19453718"></a>Bell GS, Gaitatzis A, Bell CL, Johnson AL, Sander JW. Suicide in people with epilepsy: how great is the risk? <i>Epilepsia</i>. 2009;50(8):1933-1942. doi:10.1111/j.1528-1167.2009.02106.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/19453718/pubmed" id="19453718" target="_blank">19453718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28190254">
<a name="28190254"></a>Bellivier F, Belzeaux R, Scott J, Courtet P, Golmard JL, Azorin JM. Anticonvulsants and suicide attempts in bipolar I disorders. <i>Acta Psychiatr Scand</i>. 2017;135(5):470-478. doi:10.1111/acps.12709<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/28190254/pubmed" id="28190254" target="_blank">28190254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12690085">
<a name="12690085"></a>Ben-Menachem E, Axelsen M, Johanson EH, Stagge A, Smith U. Predictors of weight loss in adults with topiramate-treated epilepsy. <i>Obes Res</i>. 2003;11(4):556-562. doi:10.1038/oby.2003.78<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/12690085/pubmed" id="12690085" target="_blank">12690085</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12760427">
<a name="12760427"></a>Ben-Zeev B, Watemberg N, Augarten A, et al. Oligohydrosis and hyperthermia: pilot study of a novel topiramate adverse effect. <i>J Child Neurol</i>. 2003;18(4):254-257. doi:10.1177/08830738030180041001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/12760427/pubmed" id="12760427" target="_blank">12760427</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet</i>. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24796492">
<a name="24796492"></a>Blodgett JC, Del Re AC, Maisel NC, Finney JW. A meta-analysis of topiramate's effects for individuals with alcohol use disorders. <i>Alcohol Clin Exp Res</i>. 2014;38(6):1481-1488. doi:10.1111/acer.12411<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/24796492/pubmed" id="24796492" target="_blank">24796492</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14982912">
<a name="14982912"></a>Brandes JL, Saper JR, Diamond M, et al. Topiramate for Migraine Prevention: A Randomized Controlled Trial. <i>JAMA</i>. 2004;291(8):965-973.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/14982912/pubmed" id="14982912" target="_blank">14982912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21482920">
<a name="21482920"></a>Bril V, England J, Franklin GM, et al; American Academy of Neurology; American Association of Neuromuscular and Electrodiagnostic Medicine; American Academy of Physical Medicine and Rehabilitation. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation [published correction appears in <i>Neurology</i>. 2011;77(6):603]. <i>Neurology</i>. 2011;76(20):1758-1765.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/21482920/pubmed" id="21482920" target="_blank">21482920</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22528274">
<a name="22528274"></a>Brophy GM, Bell R, Claassen J, et al. Guidelines For the Evaluation and Management of Status Epilepticus. <i>Neurocrit Care</i>. 2012;17(1):3-23.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/22528274/pubmed" id="22528274" target="_blank">22528274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19896679">
<a name="19896679"></a>Browning L, Parker D Jr, Liu-DeRyke X, Shah A, Coplin WM, Rhoney DH. Possible removal of topiramate by continuous renal replacement therapy. <i>J Neurol Sci</i>. 2010;288(1-2):186-189. doi:10.1016/j.jns.2009.10.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/19896679/pubmed" id="19896679" target="_blank">19896679</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27367316">
<a name="27367316"></a>Brownley KA, Berkman ND, Peat CM, et al. Binge-eating disorder in adults: a systematic review and meta-analysis. <i>Ann Intern Med</i>. 2016;165(6):409-420. doi:10.7326/M15-2455<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/27367316/pubmed" id="27367316" target="_blank">27367316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28605628">
<a name="28605628"></a>Chen LW, Chen MY, Chen KY, Lin HS, Chien CC, Yin HL. Topiramate-associated sexual dysfunction: a systematic review. <i>Epilepsy Behav</i>. 2017;73:10-17. doi:10.1016/j.yebeh.2017.05.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/28605628/pubmed" id="28605628" target="_blank">28605628</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17915969">
<a name="17915969"></a>Claudino AM, de Oliveira IR, Appolinario JC, et al. Double-blind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior therapy in binge-eating disorder. <i>J Clin Psychiatry</i>. 2007;68(9):1324-1332.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/17915969/pubmed" id="17915969" target="_blank">17915969</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17598764">
<a name="17598764"></a>Cohen AS. Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing. <i>Cephalalgia</i>. 2007;27(7):824-832.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/17598764/pubmed" id="17598764" target="_blank">17598764</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18382182">
<a name="18382182"></a>Connor GS, Edwards K, Tarsy D. Topiramate in essential tremor: findings from double-blind, placebo-controlled, crossover trials. <i>Clinical Neuropharmacol</i>. 2008;31(2):97-103.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/18382182/pubmed" id="18382182" target="_blank">18382182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27337425">
<a name="27337425"></a>Correll CU, Maayan L, Kane J, Hert MD, Cohen D. Efficacy for psychopathology and body weight and safety of topiramate-antipsychotic cotreatment in patients with schizophrenia spectrum disorders: results from a meta-analysis of randomized controlled trials.<i> J Clin Psychiatry.</i> 2016;77(6):e746-e756. doi:10.4088/JCP.15r10373<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/27337425/pubmed" id="27337425" target="_blank">27337425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29903834">
<a name="29903834"></a>Courchia B, Kurtom W, Pensirikul A, Del-Moral T, Buch M. Topiramate for seizures in preterm infants and the development of necrotizing enterocolitis. <i>Pediatrics</i>. 2018;142(1):e20173971.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/29903834/pubmed" id="29903834" target="_blank">29903834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Crone.2023">
<a name="Crone.2023"></a>Crone C, Fochtmann LJ, Attia E, et al; Guideline Writing Group<i>. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Eating Disorders</i>. 4th ed. American Psychiatric Association; 2023. doi:10.1176/appi.books.9780890424865</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22860242">
<a name="22860242"></a>Das C, Mendez G, Jagasia S, Labbate LA. Second-generation antipsychotic use in schizophrenia and associated weight gain: a critical review and meta-analysis of behavioral and pharmacologic treatments. <i>Ann Clin Psychiatry</i>. 2012;24(3):225-239.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/22860242/pubmed" id="22860242" target="_blank">22860242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10768299">
<a name="10768299"></a>DeLorenzo RJ, Sombati S, Coulter DA. Effects of topiramate on sustained repetitive firing and spontaneous recurrent seizure discharges in cultured hippocampal neurons. <i>Epilepsia</i>. 2000;41(S1):40-44. doi:10.1111/j.1528-1157.2000.tb06048.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/10768299/pubmed" id="10768299" target="_blank">10768299</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8930774">
<a name="8930774"></a>Doose DR, Walker SA, Gisclon LG, et al. Single-Dose Pharmacokinetics and Effect of Food on the Bioavailability of Topiramate, a Novel Antiepileptic Drug. <i>J Clin Pharmacol</i>, 1996;36(10):884-891.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/8930774/pubmed" id="8930774" target="_blank">8930774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31027088">
<a name="31027088"></a>Duan J, Lai J, Wang D, et al. Topiramate precipitating a manic episode in a bipolar patient comorbid with binge eating disorder: a case report. <i>Medicine (Baltimore)</i>. 2019;98(17):e15287. doi:10.1097/MD.0000000000015287<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/31027088/pubmed" id="31027088" target="_blank">31027088</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17920770">
<a name="17920770"></a>Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. <i>Pain</i>. 2007;132(3):237-251.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/17920770/pubmed" id="17920770" target="_blank">17920770</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Eprontia.1">
<a name="Eprontia.1"></a>Eprontia (topiramate) [prescribing information]. Woburn, MA: Azurity Pharmaceuticals; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22712004">
<a name="22712004"></a>Fiedorowicz JG, Miller DD, Bishop JR, Calarge CA, Ellingrod VL, Haynes WG. Systematic review and meta-analysis of pharmacological interventions for weight gain from antipsychotics and mood stabilizers. <i>Curr Psychiatry Rev</i>. 2012;8(1):25-36.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/22712004/pubmed" id="22712004" target="_blank">22712004</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28274169">
<a name="28274169"></a>Filippi L, Fiorini P, Catarzi S, et al. Safety and efficacy of topiramate in neonates with hypoxic ischemic encephalopathy treated with hypothermia (NeoNATI): a feasibility study. <i>J Matern Fetal Neonatal Med</i>. 2018;31(8):973‐980.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/28274169/pubmed" id="28274169" target="_blank">28274169</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19744111">
<a name="19744111"></a>Filippi L, la Marca G, Fiorini P, et al. Topiramate Concentrations in Neonates Treated With Prolonged Whole Body Hypothermia for Hypoxic Ischemic Encephalopathy. <i>Epilepsia</i>. 2009;50(11):2355-2361.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/19744111/pubmed" id="19744111" target="_blank">19744111</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20553846">
<a name="20553846"></a>Filippi L, Poggi C, la Marca G, et al. Oral Topiramate in Neonates With Hypoxic Ischemic Encephalopathy Treated With Hypothermia: A Safety Study. <i>J Pediatr</i>. 2010;157(3):361-366.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/20553846/pubmed" id="20553846" target="_blank">20553846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17138020">
<a name="17138020"></a>Fung EL, Nelson EA. Oligohydrosis and topiramate. <i>Pediatr Neurol</i>. 2006;35(6):446. doi:10.1016/j.pediatrneurol.2006.08.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/17138020/pubmed" id="17138020" target="_blank">17138020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15795554">
<a name="15795554"></a>Galicia SC, Lewis SL, Metman LV. Severe topiramate-associated hyperthermia resulting in persistent neurological dysfunction. <i>Clin Neuropharmacol</i>. 2005;28(2):94-95. doi:10.1097/01.wnf.0000159957.95134.1b<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/15795554/pubmed" id="15795554" target="_blank">15795554</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26185660">
<a name="26185660"></a>Giannopoulou EZ, Gortner L, Peterlini S, Gottschling S, Yilmaz U, Meyer S. Topiramate-induced nephrolithiasis. <i>Clin Case Rep</i>. 2015;3(6):508-509. doi:10.1002/ccr3.275<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/26185660/pubmed" id="26185660" target="_blank">26185660</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21555055">
<a name="21555055"></a>Glass HC, Poulin C, Shevell MI. Topiramate For the Treatment of Neonatal Seizures. <i>Pediatr Neurol</i>. 2011;44(6):439-442.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/21555055/pubmed" id="21555055" target="_blank">21555055</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9092958">
<a name="9092958"></a>Glauser TA. Preliminary Observations on Topiramate in Pediatric Epilepsies. <i>Epilepsia</i>. 1997;38(suppl 1):S37-S41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/9092958/pubmed" id="9092958" target="_blank">9092958</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16886973">
<a name="16886973"></a>Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE Treatment Guidelines: Evidence-Based Analysis of Antiepileptic Drug Efficacy and Effectiveness as Initial Monotherapy For Epileptic Seizures and Syndromes. <i>Epilepsia</i>. 2006;47(7):1094-1120.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/16886973/pubmed" id="16886973" target="_blank">16886973</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9706734">
<a name="9706734"></a>Glauser TA. Topiramate Use in Pediatric Patients. <i>Can J Neurol Sci</i>. 1998b;25(3):S8-S12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/9706734/pubmed" id="9706734" target="_blank">9706734</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22689735">
<a name="22689735"></a>Go CY, Mackay MT, Weiss SK, et a. Evidence-Based Guideline Update: Medical Treatment of Infantile Spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. <i>Neurology</i>. 2012;78(24):1974-1980.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/22689735/pubmed" id="22689735" target="_blank">22689735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23015022">
<a name="23015022"></a>Gualtieri W, Janula J. Topiramate maculopathy. <i>Int Ophthalmol</i>. 2013;33(1):103-106. doi:10.1007/s10792-012-9640-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/23015022/pubmed" id="23015022" target="_blank">23015022</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30581496">
<a name="30581496"></a>Hansen CC, Ljung H, Brodtkorb E, Reimers A. Mechanisms underlying aggressive behavior induced by antiepileptic drugs: focus on topiramate, levetiracetam, and perampanel. <i>Behav Neurol</i>. 2018;2018:2064027. doi:10.1155/2018/2064027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/30581496/pubmed" id="30581496" target="_blank">30581496</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27229356">
<a name="27229356"></a>Haque S, Shaffi M, Tang KC. Topiramate associated non-glaucomatous visual field defects. <i>J Clin Neurosci</i>. 2016;31:210-213. doi:10.1016/j.jocn.2016.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/27229356/pubmed" id="27229356" target="_blank">27229356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19398681">
<a name="19398681"></a>Harden CL, Meador KJ, Pennell PB, et al. Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. <i>Neurology</i>. 2009;73(2):133-141.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/19398681/pubmed" id="19398681" target="_blank">19398681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23216388">
<a name="23216388"></a>Hasan A, Falkai P, Wobrock T, et al; WFSBP Task force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. <i>World J Biol Psychiatry</i>. 2013;14(1):2-44. doi:10.3109/15622975.2012.739708<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/23216388/pubmed" id="23216388" target="_blank">23216388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12390646">
<a name="12390646"></a>Hershey AD, Powers SW, Vockell AL, et al. Effectiveness of Topiramate in the Prevention of Childhood Headaches. <i>Headache</i>. 2002;42(8):810-818.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/12390646/pubmed" id="12390646" target="_blank">12390646</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19496806">
<a name="19496806"></a>Hesdorffer DC, Kanner AM. The FDA alert on suicidality and antiepileptic drugs: fire or false alarm?. <i>Epilepsia</i>. 2009;50(5):978-986. doi:10.1111/j.1528-1167.2009.02012.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/19496806/pubmed" id="19496806" target="_blank">19496806</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Holt.1">
<a name="Holt.1"></a>Holt SR. Alcohol use disorder: pharmacologic management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 2, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16970741">
<a name="16970741"></a>Israni RK, Kasbekar N, Haynes K, Berns JS. Use of antiepileptic drugs in patients with kidney disease. <i>Semin Dial</i>. 2006;19(5):408-416. doi:10.1111/j.1525-139X.2006.00195.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/16970741/pubmed" id="16970741" target="_blank">16970741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jarskog.1">
<a name="Jarskog.1"></a>Jarskog LF, Yu R. Modifiable risk factors for cardiovascular disease in patients with severe mental illness. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 21, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26076842">
<a name="26076842"></a>Javed A, Cohen B, Detyniecki K, et al. Rates and predictors of patient-reported cognitive side effects of antiepileptic drugs: an extended follow-up. <i>Seizure</i>. 2015;29:34-40. doi:10.1016/j.seizure.2015.03.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/26076842/pubmed" id="26076842" target="_blank">26076842</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15351769">
<a name="15351769"></a>Johnson BA, Ait-Daoud N, Akhtar FZ, Ma JZ. Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial. <i>Arch Gen Psychiatry</i>. 2004;61(9):905-912. doi:10.1001/archpsyc.61.9.905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/15351769/pubmed" id="15351769" target="_blank">15351769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12767733">
<a name="12767733"></a>Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. <i>Lancet</i>. 2003;361(9370):1677-1685. doi:10.1016/S0140-6736(03)13370-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/12767733/pubmed" id="12767733" target="_blank">12767733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17925516">
<a name="17925516"></a>Johnson BA, Rosenthal N, Capece JA, et al; Topiramate for Alcoholism Advisory Board; Topiramate for Alcoholism Study Group. Topiramate for treating alcohol dependence: a randomized controlled trial. <i>JAMA</i>. 2007;298(14):1641-1651. doi:10.1001/jama.298.14.1641<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/17925516/pubmed" id="17925516" target="_blank">17925516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24825644">
<a name="24825644"></a>Jonas DE, Amick HR, Feltner C, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. <i>JAMA</i>. 2014;311(18):1889-1900. doi:10.1001/jama.2014.3628<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/24825644/pubmed" id="24825644" target="_blank">24825644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21479999">
<a name="21479999"></a>Kanner AM. Are antiepileptic drugs used in the treatment of migraine associated with an increased risk of suicidality? <i>Curr Pain Headache Rep</i>. 2011;15(3):164-169. doi:10.1007/s11916-011-0199-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/21479999/pubmed" id="21479999" target="_blank">21479999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10452922">
<a name="10452922"></a>Khan A, Faught E, Gilliam F, Kuzniecky R. Acute psychotic symptoms induced by topiramate. <i>Seizure</i>. 1999;8(4):235-237. doi:10.1053/seiz.1999.0287<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/10452922/pubmed" id="10452922" target="_blank">10452922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33395059">
<a name="33395059"></a>Li ST, Chu CW. Topiramate-associated urinary retention: a case report. <i>Am J Ther</i>. 2020;28(6):e759-e761. doi:10.1097/MJT.0000000000001297<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/33395059/pubmed" id="33395059" target="_blank">33395059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16062095">
<a name="16062095"></a>Ko YH, Joe SH, Jung IK, Kim SH. Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. <i>Clin Neuropharmacol. </i>2005;28(4):169-175.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/16062095/pubmed" id="16062095" target="_blank">16062095</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17621500">
<a name="17621500"></a>Korinthenberg R, Schreiner A. Topiramate in children with west syndrome: a retrospective multicenter evaluation of 100 patients. <i>J Child Neurol</i>. 2007;22(3):302-306.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/17621500/pubmed" id="17621500" target="_blank">17621500</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12366731">
<a name="12366731"></a>Kossoff EH, Pyzik PL, Furth SL, Hladky HD, Freeman JM, Vining EP. Kidney stones, carbonic anhydrase inhibitors, and the ketogenic diet. <i>Epilepsia</i>. 2002;43(10):1168-1171. doi:10.1046/j.1528-1157.2002.11302.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/12366731/pubmed" id="12366731" target="_blank">12366731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29063980">
<a name="29063980"></a>Lan YW, Hsieh JW. Bilateral acute angle closure glaucoma and myopic shift by topiramate-induced ciliochoroidal effusion: case report and literature review. <i>Int Ophthalmol</i>. 2018;38(6):2639-2648. doi:10.1007/s10792-017-0740-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/29063980/pubmed" id="29063980" target="_blank">29063980</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25847809">
<a name="25847809"></a>Lebow J, Chuy JA, Cedermark K, Cook K, Sim LA. The development or exacerbation of eating disorder symptoms after topiramate initiation. <i>Pediatrics</i>. 2015;135(5):e1312-e1316. doi:10.1542/peds.2014-3413<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/25847809/pubmed" id="25847809" target="_blank">25847809</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16647301">
<a name="16647301"></a>Lee HW, Jung DK, Suh CK, Kwon SH, Park SP. Cognitive effects of low-dose topiramate monotherapy in epilepsy patients: a 1-year follow-up. <i>Epilepsy Behav</i>. 2006;8(4):736-741. doi:10.1016/j.yebeh.2006.03.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/16647301/pubmed" id="16647301" target="_blank">16647301</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12614389">
<a name="12614389"></a>Lee S, Sziklas V, Andermann F, et al. The effects of adjunctive topiramate on cognitive function in patients with epilepsy. <i>Epilepsia</i>. 2003;44(3):339-347. doi:10.1046/j.1528-1157.2003.27402.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/12614389/pubmed" id="12614389" target="_blank">12614389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15197104">
<a name="15197104"></a>Leniger T, Thöne J, Wiemann M. Topiramate modulates pH of hippocampal CA3 neurons by combined effects on carbonic anhydrase and Cl-/HCO3- exchange. <i>Br J Pharmacol</i>. 2004;142(5):831-842. doi:10.1038/sj.bjp.0705850<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/15197104/pubmed" id="15197104" target="_blank">15197104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19255022">
<a name="19255022"></a>Lewis D, Winner P, Saper J, et al. Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Topiramate For Migraine Prevention in Pediatric Subjects 12 to 17 Years of Age. <i>Pediatrics</i>. 2009;123(3):924-934.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/19255022/pubmed" id="19255022" target="_blank">19255022</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33395059">
<a name="33395059"></a>Li ST, Chu CW. Topiramate-associated urinary retention: a case report. <i>Am J Ther</i>. 2020;28(6):e759-e761. doi:10.1097/MJT.0000000000001297<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/33395059/pubmed" id="33395059" target="_blank">33395059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23797676">
<a name="23797676"></a>Linde M, Mulleners WM, Chronicle EP, McCrory DC. Topiramate for the prophylaxis of episodic migraine in adults. <i>Cochrane Database Syst Rev.</i> 2013;(6):CD010610. doi:10.1002/14651858.CD010610<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/23797676/pubmed" id="23797676" target="_blank">23797676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21165738">
<a name="21165738"></a>Maalouf NM, Langston JP, Van Ness PC, Moe OW, Sakhaee K. Nephrolithiasis in topiramate users. <i>Urol Res</i>. 2011;39(4):303-307. doi:10.1007/s00240-010-0347-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/21165738/pubmed" id="21165738" target="_blank">21165738</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23277264">
<a name="23277264"></a>Mahmood S, Booker I, Huang J, Coleman CI. Effect of topiramate on weight gain in patients receiving atypical antipsychotic agents. <i>J Clin Psychopharmacol</i>. 2013;33(1):90-94.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/23277264/pubmed" id="23277264" target="_blank">23277264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24725807">
<a name="24725807"></a>Manitpisitkul P, Curtin CR, Shalayda K, Wang SS, Ford L, Heald DL. Pharmacokinetics of topiramate in patients with renal impairment, end-stage renal disease undergoing hemodialysis, or hepatic impairment. <i>Epilepsy Res</i>. 2014;108(5):891-901. doi:10.1016/j.eplepsyres.2014.03.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/24725807/pubmed" id="24725807" target="_blank">24725807</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19050411">
<a name="19050411"></a>Margari L, Ventura P, Buttiglione M, et al. Electrophysiological study in 2 children with transient hypohidrosis induced by topiramate. <i>Clin Neuropharmacol</i>. 2008;31(6):339-346. doi:10.1097/WNF.0b013e3181646cf2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/19050411/pubmed" id="19050411" target="_blank">19050411</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Matharu.1">
<a name="Matharu.1"></a>Matharu MS, Cohen AS. Short-lasting unilateral neuralgiform headache attacks: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 6, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16987158">
<a name="16987158"></a>May A, Leone M, Afra J, et al; EFNS Task Force. EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias. <i>Eur J Neurol</i>. 2006;13(10):1066-1077.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/16987158/pubmed" id="16987158" target="_blank">16987158</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-May.1">
<a name="May.1"></a>May A. Cluster headache: Treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 8, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12562571">
<a name="12562571"></a>McElroy SL, Arnold LM, Shapira NA, et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial [published correction appears in <i>Am J Psychiatry</i>. 2003;160(3):612]. <i>Am J Psychiatry</i>. 2003;160(2):255-261. doi:10.1176/appi.ajp.160.2.255<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/12562571/pubmed" id="12562571" target="_blank">12562571</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17258690">
<a name="17258690"></a>McElroy SL, Hudson JI, Capece JA, Beyers K, Fisher AC, Rosenthal NR; Topiramate Binge Eating Disorder Research Group. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. <i>Biol Psychiatry</i>. 2007;61(9):1039-1048. doi:10.1016/j.biopsych.2006.08.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/17258690/pubmed" id="17258690" target="_blank">17258690</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22303523">
<a name="22303523"></a>McIntyre RS, Alsuwaidan M, Goldstein BI, et al; Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force recommendations for the management of patients with mood disorders and comorbid metabolic disorders. <i>Ann Clin Psych. </i>2012;24(1):69-81.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/22303523/pubmed" id="22303523" target="_blank">22303523</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15509246">
<a name="15509246"></a>Mikaeloff Y, Rey E, Soufflet C, et al. Topiramate Pharmacokinetics in Children With Epilepsy Aged From 6 Months to 4 Years. <i>Epilepsia</i>. 2004;45(11):1448-1452.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/15509246/pubmed" id="15509246" target="_blank">15509246</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23861645">
<a name="23861645"></a>Minton GC, Miller AD, Bookstaver PB, Love BL. Topiramate: safety and efficacy of its use in the prevention and treatment of migraine. <i>J Cent Nerv Syst Dis</i>. 2011;3:155-168. doi:10.4137/JCNSD.S4365<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/23861645/pubmed" id="23861645" target="_blank">23861645</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24636967">
<a name="24636967"></a>Mizuno Y, Suzuki T, Nakagawa A, et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. <i>Schizophren Bull. </i>2014;40(6):1385-1403.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/24636967/pubmed" id="24636967" target="_blank">24636967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34848414">
<a name="34848414"></a>Muaddi L, Osman O, Clark B. Topiramate-induced severe electrolyte abnormalities and hypernatremia leading to central pontine myelinolysis. <i>BMJ Case Rep</i>. 2021;14(11):e245870. doi:10.1136/bcr-2021-245870<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/34848414/pubmed" id="34848414" target="_blank">34848414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25083242">
<a name="25083242"></a>Mula M. Topiramate and cognitive impairment: evidence and clinical implications. <i>Ther Adv Drug Saf</i>. 2012;3(6):279-289. doi:10.1177/2042098612455357<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/25083242/pubmed" id="25083242" target="_blank">25083242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19178563">
<a name="19178563"></a>Mula M, Hesdorffer DC, Trimble M, Sander JW. The role of titration schedule of topiramate for the development of depression in patients with epilepsy. <i>Epilepsia</i>. 2009;50(5):1072-1076. doi:10.1111/j.1528-1167.2008.01799.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/19178563/pubmed" id="19178563" target="_blank">19178563</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22994856">
<a name="22994856"></a>Mula M, Kanner AM, Schmitz B, Schachter S. Antiepileptic drugs and suicidality: an expert consensus statement from the Task Force on Therapeutic Strategies of the ILAE Commission on Neuropsychobiology. <i>Epilepsia</i>. 2013;54(1):199-203. doi:10.1111/j.1528-1167.2012.03688.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/22994856/pubmed" id="22994856" target="_blank">22994856</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12752464">
<a name="12752464"></a>Mula M, Trimble MR, Lhatoo SD, Sander JW. Topiramate and psychiatric adverse events in patients with epilepsy. <i>Epilepsia</i>. 2003;44(5):659-663. doi:10.1046/j.1528-1157.2003.05402.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/12752464/pubmed" id="12752464" target="_blank">12752464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26835388">
<a name="26835388"></a>Nelson GR. Management of infantile spasms. <i>Transl Pediatr</i>. 2015;4(4):260-270.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/26835388/pubmed" id="26835388" target="_blank">26835388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31091527">
<a name="31091527"></a>Nuñez-Ramiro A, Benavente-Fernández I, Valverde E, et al. Topiramate plus cooling for hypoxic-ischemic encephalopathy: a randomized, controlled, multicenter, double-blinded trial. <i>Neonatology</i>. 2019;116(1):76‐84.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/31091527/pubmed" id="31091527" target="_blank">31091527</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12366729">
<a name="12366729"></a>Ohman I, Vitols S, Luef G, et al. Topiramate Kinetics During Delivery, Lactation, and in the Neonate: Preliminary Observations. <i>Epilepsia</i>. 2002;43(10):1157-1160.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/12366729/pubmed" id="12366729" target="_blank">12366729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19740626">
<a name="19740626"></a>Ohman I, Sabers A, de Flon P, et al. Pharmacokinetics of Topiramate During Pregnancy. <i>Epilepsy Res</i>. 2009;87(2-3):124-129.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/19740626/pubmed" id="19740626" target="_blank">19740626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16436648">
<a name="16436648"></a>Ondo WG, Jankovic J, Connor GS, et al; Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double-blind, placebo-controlled trial. <i>Neurology</i>. 2006;66(5):672-677.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/16436648/pubmed" id="16436648" target="_blank">16436648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31413170">
<a name="31413170"></a>Oskoui M, Pringsheim T, Billinghurst L, et al. Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society [published correction appears in <i>Neurology</i>. 2020;94(1):50]. <i>Neurology</i>. 2019;93(11):500-509.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/31413170/pubmed" id="31413170" target="_blank">31413170</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17355498">
<a name="17355498"></a>Pascual J, Láinez MJ, Dodick D, Hering-Hanit R. Antiepileptic drugs for the treatment of chronic and episodic cluster headache: a review. <i>Headache.</i> 2007;47(1):81-89.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/17355498/pubmed" id="17355498" target="_blank">17355498</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24434533">
<a name="24434533"></a>Pasini A, Pitzianti M, Baratta A, Moavero R, Curatolo P. Timing and clinical characteristics of topiramate-induced psychosis in a patient with epilepsy and tuberous sclerosis. <i>Clin Neuropharmacol</i>. 2014;37(1):38-39. doi:10.1097/WNF.0000000000000014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/24434533/pubmed" id="24434533" target="_blank">24434533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10545555">
<a name="10545555"></a>Pellock JM. Managing Pediatric Epilepsy Syndromes With New Antiepileptic Drugs. <i>Pediatrics</i>. 1999;104(5, pt 1):1106-1116.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/10545555/pubmed" id="10545555" target="_blank">10545555</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9264038">
<a name="9264038"></a>Perucca E. A pharmacological and clinical review on topiramate, a new antiepileptic drug. <i>Pharmacol Res</i>. 1997;35(4):241-256. doi:10.1006/phrs.1997.0124<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/9264038/pubmed" id="9264038" target="_blank">9264038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-QudexyXR.1">
<a name="QudexyXR.1"></a>Qudexy XR (topiramate) extended-release capsules [prescribing information]. Maple Grove, MN: Upsher-Smith Laboratories LLC; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28699493">
<a name="28699493"></a>Register SL, Ruano OL, Sanchez DL, Catalano G, Catalano MC. Hallucinations associated with topiramate therapy: a case report and review of the literature. <i>Curr Drug Saf</i>. 2017;12(3):193-197. doi:10.2174/1574886312666170710190820<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/28699493/pubmed" id="28699493" target="_blank">28699493</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29301420">
<a name="29301420"></a>Reus VI, Fochtmann LJ, Bukstein O, et al. The American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder. <i>Am J Psychiatry</i>. 2018;175(1):86-90. doi:10.1176/appi.ajp.2017.1750101<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/29301420/pubmed" id="29301420" target="_blank">29301420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20443647">
<a name="20443647"></a>Richa S, Yazbek JC. Ocular adverse effects of common psychotropic agents: a review. <i>CNS Drugs</i>. 2010;24(6):501-526. doi:10.2165/11533180-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/20443647/pubmed" id="20443647" target="_blank">20443647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23007795">
<a name="23007795"></a>Riesgo R, Winckler MI, Ohlweiler L, et al. Treatment of refractory neonatal seizures with topiramate. <i>Neuropediatrics</i>. 2012;43(6):353‐356.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/23007795/pubmed" id="23007795" target="_blank">23007795</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32541330">
<a name="32541330"></a>Rissardo JP, Caprara ALF. Topiramate-associated movement disorder: case series and literature review. <i>Clin Neuropharmacol</i>. 2020;43(4):116-120. doi:10.1097/WNF.0000000000000395<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/32541330/pubmed" id="32541330" target="_blank">32541330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10371378">
<a name="10371378"></a>Rosenfeld WE, Doose DR, Walker SA, et al. A Study of Topiramate Pharmacokinetics and Tolerability in Children With Epilepsy. <i>Pediatr Neurol</i>. 1999;20(5):339-344.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/10371378/pubmed" id="10371378" target="_blank">10371378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12450969">
<a name="12450969"></a>Rosenow F, Knake S, Hebebrand J. Topiramate and anorexia nervosa. <i>Am J Psychiatry</i>. 2002;159(12):2112-2113. doi:10.1176/appi.ajp.159.12.2112-a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/12450969/pubmed" id="12450969" target="_blank">12450969</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9592618">
<a name="9592618"></a>Sachdeo RC. Topiramate. Clinical Profile in Epilepsy. <i>Clin Pharmacokinet</i>. 1998;34(5):335-346.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/9592618/pubmed" id="9592618" target="_blank">9592618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Schachter.1">
<a name="Schachter.1"></a>Schachter SC. Overview of the management of epilepsy in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 9, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26809953">
<a name="26809953"></a>Sedighi B, Shafiei K, Azizpour I. Topiramate-induced paresthesia is more frequently reported by migraine than epileptic patients. <i>Neurol Sci</i>. 2016;37(4):585-589. doi:10.1007/s10072-015-2458-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/26809953/pubmed" id="26809953" target="_blank">26809953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30591244">
<a name="30591244"></a>Sierra-Rodríguez MA, Rodríguez-Vicente L, Chavarri-García JJ, Del Río-Mayor JL. Acute narrow-angle glaucoma induced by topiramate with acute myopia and macular striae: a case report. 2019;94(3):130-133. doi:10.1016/j.oftal.2018.11.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/30591244/pubmed" id="30591244" target="_blank">30591244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18639748">
<a name="18639748"></a>Silverstein FS, Ferriero DM. Off-Label Use of Antiepileptic Drugs For the Treatment of Neonatal Seizures. <i>Pediatr Neurol</i>. 2008;39(2):77-79.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/18639748/pubmed" id="18639748" target="_blank">18639748</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30755834">
<a name="30755834"></a>Sinha A, Oo P, Asghar MU, et al. Type II renal tubular acidosis secondary to topiramate: a review. <i>Cureus</i>. 2018;10(11):e3635. doi:10.7759/cureus.3635<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/30755834/pubmed" id="30755834" target="_blank">30755834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20458347">
<a name="20458347"></a>Sommer BR, Fenn HH. Review of topiramate for the treatment of epilepsy in elderly patients. <i>Clin Interv Aging.</i> 2010;5:89-99.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/20458347/pubmed" id="20458347" target="_blank">20458347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31113373">
<a name="31113373"></a>Steiner TJ, Jensen R, Katsarava Z, et al. Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign Against Headache. <i>J Headache Pain</i>. 2019;20(1):57. doi:10.1186/s10194-018-0899-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/31113373/pubmed" id="31113373" target="_blank">31113373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11442157">
<a name="11442157"></a>Takeoka M, Holmes GL, Thiele E, et al. Topiramate and metabolic acidosis in pediatric epilepsy. <i>Epilepsia</i>. 2001;42(3):387-392. doi:10.1046/j.1528-1157.2001.04500.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/11442157/pubmed" id="11442157" target="_blank">11442157</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12199733">
<a name="12199733"></a>Takeoka M, Riviello JJ Jr, Pfeifer H, Thiele EA. Concomitant treatment with topiramate and ketogenic diet in pediatric epilepsy. <i>Epilepsia</i>. 2002;43(9):1072-1075. doi:10.1046/j.1528-1157.2002.00602.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/12199733/pubmed" id="12199733" target="_blank">12199733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26543812">
<a name="26543812"></a>Tantikittichaikul S, Johnson J, Laengvejkal P, DeToledo J. Topiramate-induced hyperammonemic encephalopathy in a patient with mental retardation: a case report and review of the literature. <i>Epilepsy Behav Case Rep</i>. 2015;4:84-85. doi:10.1016/j.ebcr.2014.09.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/26543812/pubmed" id="26543812" target="_blank">26543812</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Topamax.2">
<a name="Topamax.2"></a>Topamax Tablets and Sprinkle Capsules (topiramate) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Topamax.3">
<a name="Topamax.3"></a>Topamax (topiramate) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-TrokendiXR.1">
<a name="TrokendiXR.1"></a>Trokendi XR (topiramate) extended-release capsules [prescribing information]. Rockville, MD: Supernus Pharmaceuticals Inc; February 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-TrokendiXR.2">
<a name="TrokendiXR.2"></a>Trokendi XR (topiramate) extended-release capsules [prescribing information]. Winchester, KY: Catalent Pharma Solutions; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25207478">
<a name="25207478"></a>Tsien MZ, Cordova J, Qadir A, Zhao L, Hart J, Azzam R. Topiramate-induced acute liver failure in a pediatric patient: a case report and review of literature. <i>J Pediatr Gastroenterol Nutr</i>. 2016;63(3):e37-e38. doi:10.1097/MPG.0000000000000566<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/25207478/pubmed" id="25207478" target="_blank">25207478</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27789806">
<a name="27789806"></a>Türe H, Keskin Ö, Çakır Ü, Aykut Bingöl C, Türe U. The frequency and severity of metabolic acidosis related to topiramate. <i>J Int Med Res</i>. 2016;44(6):1376-1380. doi:10.1177/0300060516669897<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/27789806/pubmed" id="27789806" target="_blank">27789806</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34315425">
<a name="34315425"></a>Tyagi M, Behera S, Senthil S, Pappuru RR, Ambiya V, Dikshit S. Topiramate induced bilateral hypopyon uveitis and choroidal detachment: a report of two cases and review of literature. <i>BMC Ophthalmol</i>. 2021;21(1):287. doi:10.1186/s12886-021-02050-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/34315425/pubmed" id="34315425" target="_blank">34315425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet</i>. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 9, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30600626">
<a name="30600626"></a>Vancampfort D, Firth J, Correll CU, et al. The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials. <i>World Psychiatry.</i> 2019;18(1):53-66. doi:10.1002/wps.20614<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/30600626/pubmed" id="30600626" target="_blank">30600626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21684121">
<a name="21684121"></a>Verrotti A, Scaparrotta A, Agostinelli S, Di Pillo S, Chiarelli F, Grosso S. Topiramate-induced weight loss: a review. <i>Epilepsy Res</i>. 2011;95(3):189-199. doi:10.1016/j.eplepsyres.2011.05.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/21684121/pubmed" id="21684121" target="_blank">21684121</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26068002">
<a name="26068002"></a>Weber A, Cole JW, Mytinger JR. Infantile spasms respond poorly to topiramate. <i>Pediatr Neurol</i>. 2015;53(2):130-134.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/26068002/pubmed" id="26068002" target="_blank">26068002</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16997051">
<a name="16997051"></a>Welch BJ, Graybeal D, Moe OW, Maalouf NM, Sakhaee K. Biochemical and stone-risk profiles with topiramate treatment. <i>Am J Kidney Dis</i>. 2006;48(4):555-563. doi:10.1053/j.ajkd.2006.07.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/16997051/pubmed" id="16997051" target="_blank">16997051</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25667861">
<a name="25667861"></a>Westergren T, Hjelmeland K, Kristoffersen B, Johannessen SI, Kalikstad B. Probable topiramate-induced diarrhea in a 2-month-old breast-fed child - a case report.<i> Epilepsy Behav Case Rep</i>. 2014;(2):22-23.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/25667861/pubmed" id="25667861" target="_blank">25667861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19178558">
<a name="19178558"></a>Westin AA, Nakken KO, Johannessen SI, et al. Serum Concentration/dose Ratio of Topiramate During Pregnancy. <i>Epilepsia</i>. 2009;50(3):480-485.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/19178558/pubmed" id="19178558" target="_blank">19178558</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23996081">
<a name="23996081"></a>Wiffen PJ, Derry S, Lunn MP, Moore RA. Topiramate for neuropathic pain and fibromyalgia in adults. <i>Cochrane Database Syst Rev</i>. 2013;(8):CD008314. doi: 10.1002/14651858.CD008314.pub3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/23996081/pubmed" id="23996081" target="_blank">23996081</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16324162">
<a name="16324162"></a>Winner P, Pearlman EM, Linder SL, et al. Topiramate For Migraine Prevention in Children: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Headache</i>. 2005;45(10):1304-1312.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/16324162/pubmed" id="16324162" target="_blank">16324162</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Yager.1">
<a name="Yager.1"></a>Yager J, Devlin MJ, Halmi KA, et al; American Psychiatric Association. Practice guideline for the treatment of patients with eating disorders, 3rd edition. http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/eatingdisorders.pdf. Published June 2006.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Yager.2">
<a name="Yager.2"></a>Yager J, Devlin MJ, Halmi KA, et al; American Psychiatric Association. Guideline watch (August 2012): practice guideline for the treatment of patients with eating disorders, 3rd edition. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/eatingdisorders-watch.pdf. Published August 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23409971">
<a name="23409971"></a>Yamamoto Y, Takahashi Y, Imai K, et al. Risk factors for hyperammonemia in pediatric patients with epilepsy. <i>Epilepsia</i>. 2013;54(6):983-989. doi:10.1111/epi.12125<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/23409971/pubmed" id="23409971" target="_blank">23409971</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22013182">
<a name="22013182"></a>Zesiewicz TA, Elble RJ, Louis ED, et al. Evidence-based guideline update: treatment of essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2011;77(19):1752-1755. doi:10.1212/WNL.0b013e318236f0fd<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/22013182/pubmed" id="22013182" target="_blank">22013182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10768302">
<a name="10768302"></a>Zhang X, Velumian AA, Jones OT, Carlen PL. Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. <i>Epilepsia</i>. 2000;41(S1):52-60. doi:10.1111/j.1528-1157.2000.tb02173.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/10768302/pubmed" id="10768302" target="_blank">10768302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30546312">
<a name="30546312"></a>Zhuo C, Xu Y, Liu S, et al. Topiramate and metformin are effective add-on treatments in controlling antipsychotic-induced weight gain: a systematic review and network meta-analysis. <i>Front Pharmacol.</i> 2018;9:1393. doi:10.3389/fphar.2018.01393<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/30546312/pubmed" id="30546312" target="_blank">30546312</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18382180">
<a name="18382180"></a>Zou LP, Lin Q, Qin J, et al. Evaluation of open-label topiramate as primary or adjunctive therapy in infantile spasms. <i>Clin Neuropharmacol</i>. 2008;31(2):86-92.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/18382180/pubmed" id="18382180" target="_blank">18382180</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12851 Version 699.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
